Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
1 
 CLINICAL STUDY PROTOCOL   
X16035  
 
A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell 
Transplantation Followed By [CONTACT_207101], MLN9708,  in Patients with High -risk Hematologic Malig nancies  
 
 
 
 
 
 
Indication:  High Risk Hematologic Malignancies  
Phase:  Phase II  
 
Protocol History  
Original    [ADDRESS_246937]. NE   Suite 1000  
Atlanta, GA  [ZIP_CODE]  
[PHONE_4451]  
 
 
 
 
 
 
This is an investigator -initiated study.  The principal investigator [INVESTIGATOR_73808] R. Solomon, MD , (who 
may also be referred to as the sponsor -investigator), is conducting the study and acting as the 
sponsor.  Therefore, the legal/ethical obligations of the principal investigator [INVESTIGATOR_20531] a sponsor and those of an investigator.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
2 
 PROTOCOL SUMMARY   
Study Title:   A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell 
Transplantation Followed By [CONTACT_207101], MLN9708,  in Patients with High -risk Hematologic Malignancies  
Phase :  II 
Number of Patients:   25 
Study O bjectives   
Primary  
 To estimate the incidence  of relapse/progression at one -year post -transplant.  
Secondary  
 To ob tain estimates of overall survival (OS), event -free survival (EFS), non -relapse mortality 
(NRM), engraftment, acute and chronic graft -versus -host disease (GVHD).  
 Characterize additional hematologic and non -hematologic toxicities of MLN9078 when given 
post haploidentical transplant.  
 Characterize donor hematopoietic chimerism in peripheral blood at days ~30, ~60, and ~[ADDRESS_246938].  
 
Overview of Study Design:    
In an attempt to reduce relapse risk and improve outcomes following haploidentical transplantation  
for patients with high risk hematologic malignancies, we will implement several strategies to 
augment the well documented effect of NK cell alloreactivity seen in HLA -mismatched 
transplantation. These strategies include  (1) choosing potential haploidentic al donors for optimal 
NK-alloreactivity, (2) utilizing proteasome inhibition post -transplant with MLN9708 to both 
sensitize tumor  cells to NK cytotoxicity and protect against graft -versus -host disease (GVHD), and 
(3) eliminating mycophenolate mofetil from the post -transplant  immunosuppression regimen to 
improve NK cell reconstitution following haploidentical peripheral blood stem cell transplantation.  
Patients will receive a nonmyeloablative haploidentical transplant using a T -cell replete allograft and 
post-transplant cyclophosphamide as previously described  at our center (Bashey et al. J Clin Oncol. 
2013; 31(10):1310 -6).  MLN9708 will be administered  once  weekly for [ADDRESS_246939] of tacrolimus only 
(MLN9708 will substitute for mycophenolate mofetil as the second GVHD prophylactic 
medication).  
The primary endpoint of this trial will be the risk of relapse and/or progression at one -year post -
transplant. Experience from th e literature suggests that following  a nonmyeloablative haploidentical 
transplant using post -transplant cyclophosphamide (haplo -pCy), the risk of relapse is approximately 
50% at one year  post-transplant .  It is hoped that under this protocol, this rate wil l be at most 25%. 
Thus we statistically formalize this study by [CONTACT_207102]  p, the PFS rate is 0.25 or 
less versus the alternative hypothesis that p is greater than 0.5. A sample size of 25 patients gives 
90% power with an alpha=0.05,  using the formula for a one sample binomial (two -sided) test of a 
proportion.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
3 
 Correlative samples will be drawn at baseline, day 30, 60, 90, 6mo, 12 months for lymphocyte 
subsets.  Additional PBMCs will be collected and frozen for future immune reconstitut ion studies.  
Approximately 30 -50ml of blood will be collected at each time point.  
Study Population:    
Eligible patients will be at least [ADDRESS_246940] a high risk hematologic malignancy (a cute lymphoblastic leukemia/lymphoma in 
complete remission, acute myeloid leukemia in complete remission, relapsed Burkitt 
leukemia/lymphoma in complete remission, multiple myeloma (relapsed disease and/or presence of 
del17p), relapsed ly mphoma including ma rginal zone, follicular, and chemotherapy -sensitive diffuse 
large B cell, T ce ll, Mantle cell, and Hodgkin’s.  Full details of disease inclusion is located in section 
5.1. Key Exclusion Criteria will be p oor performance sta tus, inadequate organ function, o r lack of 
suitable haploidentical donor.  
Duration of Study:   # months from FPI [INVESTIGATOR_207076]: 24 months  
# months from LPI [INVESTIGATOR_207077]: 12 months.  
# months to complete study: 36 months   
 
 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
4 
  
STUDY OVERVIEW  
 
 
 
Days –6, -5 Fludarabine 30 mg/M2 IV qd  
 Cyclophosphamide ( CTX) 14.5 mg/kg IV qd  
  
  
  
 
Days –4 -2 Fludarabine 30 mg/M2 IV qd  
 
  
 
Day –1 TBI 200 cGy  
 
  
 
Day 0  Infuse unmanipulated PBSCs  
 
  
 
Days 3, 4  CTX 50 mg/kg IV q d  
 (hydration/Mesna)  
(First dose of cyclophosphamide must be administered 48 -72 hr after inf usion of PBCs)  
  
 
Day 5    Begin Tacrolimus  and  
                MLN9708 4mg weekly x 3doses q28days, up to 12 monthly cycles  
 
  
 
Day 30 , 60, 90  Assess Chimerism in peripheral blood  
 
  
  
Day 180  Discontinue Tacrolimus  
 
 
 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
[ADDRESS_246941] Screen  Month 1 
(4 
weekly 
visits ) Month 
2 (4 
weekly 
visit)  Month 
3 (4 
weekly 
visits)  Month 
4 Month 
5 Month 
6 Month s 
7-11 Month 
12 End of 
Study  Months 
18, 24 
and 36  
H & P  X X X X X X X X X X X 
CBC with 
differential  X X X X X X X X X X X 
Chemistry  X X X X X X X X X X X 
PFT* X           
ECHO * X           
EKG*  X           
IDMs including 
Hepatitis & 
HIV* X           
Pregnancy test 
**(FOCBP)  X           
GVHD 
assessment   X X X X X X X X X X 
Toxicity 
Assessment   X X X X X X X X X X 
Bone marrow 
biopsy & 
aspi[INVESTIGATOR_56607]     X   X  X X X 
CT/PET for 
NHL/HD for 
disease 
assessment     X   X  X X X 
Research 
Sample ***  X X (Day 
30) X (Day 
60) X (Day 
90)   X  X   
Survival            X 
New 
malignancy 
assessment            X 
*Testing that is done for transplant  is acceptable if done within 6 weeks  of the start of study drug.   
**Women with a uterus <50 or women >50 but < one year without a menstrual cycle) are considered 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
6 
 FOCBP.  
*** Research samples will be collected for lymphocyte subsets.  Additional PBMCs will be collected 
to be frozen for future immune reconstitution studies. Approximately 30 -50ml of blood will be 
collected at each time point.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
[ADDRESS_246942] UDY RATIONALE  ................................ ...............................  14 
1.1 Scientific Background  ................................ ................................ ................................ .. 14 
1.1.1  Disease Under Treatment  ................................ ................................ ......................  17 
1.1.2  MLN9708  ................................ ................................ ................................ ..............  18 
1.2 Preclinical Experience  ................................ ................................ ................................ . 18 
1.3 Clinical Experience  ................................ ................................ ................................ ...... 18 
1.4 Pharmacokinetics and Drug Metabolism  ................................ ................................ ..... 18 
1.5 Clinical Trial Experience Using the Oral Formulation of MLN9708  .........................  19 
1.6 Relapsed and/or Refractory Multiple Myeloma  ................................ ..........................  23 
1.7 Newly Diagnosed Multiple Myeloma (NDMM)  ................................ .........................  26 
1.8 Study Rationale  ................................ ................................ ................................ ............  28 
1.9 Potential Risks and Benefits  ................................ ................................ ........................  29 
2. STUDY OBJECTIVES  ................................ ................................ ................................ ...... 33 
2.1 Primary Objectives  ................................ ................................ ................................ ...... 33 
2.2 Secondary Objectives  ................................ ................................ ................................ .. 33 
3. STUDY ENDPOINTS  ................................ ................................ ................................ ....... 33 
3.1 Primary Endpoints  ................................ ................................ ................................ ....... 33 
3.2 Secondary Endpoints  ................................ ................................ ................................ ... 33 
4. STUDY DESIGN ................................ ................................ ................................ ...............  33 
4.1 Overview of Study Design  ................................ ................................ ...........................  33 
4.2 Number of Patients  ................................ ................................ ................................ ...... 35 
4.3 Duration o f Study  ................................ ................................ ................................ .........  35 
4.4 Correlative Samples  ................................ ................................ ................................ ..... 35 
5. STUDY POPULATION  ................................ ................................ ................................ .... 35 
5.1 Inclusion Criteria  ................................ ................................ ................................ .........  35 
5.2 Exclusion Criteria  ................................ ................................ ................................ ........  37 
5.3 Criteria for donor selection  ................................ ................................ ..........................  39 
6. TREATMENT PLAN /STUDY DRUG  ................................ ................................ .............  39 
6.1 Transplant  Regimen  ................................ ................................ ................................ ..... 39  
6.2 MLN9708 Administration  ................................ ................................ ...........................  42 
6.3 Dose -Modification Guidelines  ................................ ................................ .....................  43 
 6.3.1 R ecommended  MLN9708 Criteria for Beginning or Delaying a Subsequent 
Treatment Cycle & Dose Modifications for Treatment Associated Toxicity   ..... 43 
6.4 Excluded Concomitant Medications and Procedures  ................................ ..................  46 
6.5 Permitted Concomitant Medications and Procedures  ................................ ..................  47 
6.6 Precautions and Restrictions  ................................ ................................ ........................  47 
6.7 Management of Clinical Events  ................................ ................................ ...................  48 
6.8 Preparation, Reconstitution, and Dispensing  ................................ ...............................  51 
6.9 Packaging and L abeling  ................................ ................................ ...............................  51 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
8 
 6.10 Storage, Handling, and Accountability  ................................ ................................ ...... 51 
6.11 Study Compliance  ................................ ................................ ................................ ...... 52 
6.12 Termination of Treatment and/or Study Participation  ................................ ...............  [ADDRESS_246943] Rete ntion  ................................ ................................ ................................ ....... 62 
10. USE OF INFORMATI ON ................................ ................................ ...............................  62 
11. DISEASE EVALUATION……………………………………………………………..  63 
12. REFERENCES  ................................ ................................ ................................ ................  71 
13. APPENDICES  ................................ ................................ ................................ .................  79 
13.1 Karnofsky Performance Status  .. …………………………………………………… 79 
13.2 Group B KIR Haplotype Determination  ................................ ................................ .... 80 
13.3 Sample SAE Form  ................................ ................................ ................................ ..... 80 
13.4 Millennium Pregnancy Reporting Form  ................................ ................................ .... 80 
 
 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
[ADDRESS_246944] OF TABLES   
Table 1 -1: Ongoing Studies of Oral MLN9708  
Table 1 -2: Summary of Most Common (At Least 10% of Total) All Grade Treatment -Emergent 
Adverse Events (Oral MLN9708 Single -Agent [C16003/4/7/9] Safety Populat ion) 
Table 1 -3: Summary of Most Common (At Least 10% of Total) All Grade Treatment -Emergent 
Adverse Events (Oral MLN9708 Combination -Agent [C16005/6/8] Safety Population)  
Table 1 -4: Study C16004, Oral MLN9708, Single Agent, Given Weekly: Most Common TEAEs 
as of 30 April 12 (N=52)  
Table 1 -5: Study C16007, Oral MLN9708, Single Agent Given Weekly, Most Common TEAEs 
as of 30April 12 (N=14)  
Table 1 -6: Study C16005: Oral MLN97087 Given Weekly in Combination With L enalidomide  
and De xamethasone , Most Common TEAEs a s of 30 April 2012  
Table 6 -1: MLN908 Dose Adjustments  
Table 6 -2: MLN9708 Dose  Adjustments for Hematologic Toxicities  
Table 6 -3: MLN9708 Treatment Modification (Delays, Reductions, and Discontinuations) Due 
to Adverse Events (Non -Hematologic Toxicities)  
Table 11 -1: Response Criteria for Lymphoma  
 
 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
[ADDRESS_246945] cancer resistance protein  
hCG beta-human chorionic gonadotropin  
BID bis in die; twice a day  
BM bone marrow  
BSA  body surface area  
BUN  blood urea nitrogen  
BZD  Benzodiazepi[INVESTIGATOR_207078], IV dosing  
CL P plasma clearance  
CL Total total clearance  
Cmax single -dose maximum (peak) concentration   
CNS  central nervous system  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
[ADDRESS_246946] computed tomography  
Ctrough single -dose end of dosing interval (trough) concentration  
CV cardiovascular  
CYP  cytochrome P 450 
DLT  dose-limiting toxicity  
DME  drug metabolizing enzymes  
DNA  deoxyribonucleic acid  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EDC  electronic data capture  
ELISA  enzyme -linked immunosorbent assay  
EOS  End o f Study (visit)  
EOT  End of Treatment (visit)  
EU European Union  
FDA  [LOCATION_002] Food and Drug Administration  
GCP  Good Clinical Practice  
G-CSF granulocyte colony stimulating factor  
GGT  gamma glutamyl transferase  
GI Gastrointestinal  
GLP  Good Laborat ory Practices  
GM-CSF granulocyte macrophage -colony stimulating factor  
GMP  Good Manufacturing Practice  
Hb Hemoglobin  
Hct Hematocrit  
HDPE  high-density polyethylene  
hERG  human ether -à-go-go related gene  
HIV human immunodeficiency virus  
HNSTD  highest n onseverely toxic dose  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
12 
 Abbreviation  Term  
IB Investigator’s Brochure  
IC50 concentration producing 50% inhibition  
ICF informed consent form  
ICH International Conference on Harmonisation  
IEC independent ethics committee  
IRB institutional review board  
ITT intent -to-treat 
IV intravenous; intravenously  
IVRS  interactive voice response system  
Ki inhibition constant  
KPS Karnofsky Performance Status  
LDH  lactate dehydrogenase  
LFT liver function test(s)  
MedDRA  Medical Dictionary for Regulatory Activities  
Millennium  Millenn ium Pharmaceuticals, Inc., and its affiliates  
MRI  magnetic resonance imaging  
MRU  medical resource utilization  
MTD  maximum tolerated dose  
MUGA  multiple gated acquisition (scan)  
NCCN  National Comprehensive Cancer Network  
NCI National Cancer Institute  
NCI CTCAE  National Cancer Institute Common Terminology Criteria for Adverse Events  
NPO  nothing by [CONTACT_207103] (disease progression)  
Pgp P-glycoprotein  
PK pharmacokinetic(s)  
PO per os ; by [CONTACT_1966] (orally)  
PR partial remission  
PRO  patient -reported outcome  
PSA prostate -specific antigen  
QD quaque die ; each day; once daily  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
13 
 Abbreviation  Term  
QID quater in die;  4 times a day  
QOD  quaque altera die ; every  other day  
QOL  quality of life  
QTc rate-corrected QT interval (millisec) of electrocardiograph  
RBC  red blood cell  
RECIST  Response Evaluation Criteria in Solid Tumors  
SAE  serious adverse event  
SC Subcutaneous  
SD stable disease  
SmPC  Summary of Produc t Characteristics  
t1/2 terminal disposition half -life 
TGI tumor growth inhibition  
Tmax single -dose time to reach maximum (peak) concentration  
[LOCATION_006] [LOCATION_008]  
ULN  upper limit of the normal range  
US [LOCATION_002]  
Vz volume of distribution in the ter minal phase  
WBC  white blood cell  
WHO  World Health Organization  
 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
[ADDRESS_246947]: 1) volunteer 
unrelated donors; 2) umbilical cord blood; and 3) partially HLA -matched, or haploidentical, 
related donors3.  Since any patient shares exactly one HLA haplotype with  each biological parent 
or child and half  of siblings, an eligible haploidentical donor can be identified rapi[INVESTIGATOR_207079].  However, haploidentical HSCT has been associated with significant risks of graft 
rejection and severe GVHD4-6, which are manifestations of excessive alloreactivity by [CONTACT_207104]7 and 
donor T cells8, respectively.  The risk of severe GVHD may be reduced in i ntensively 
conditioned recipi[INVESTIGATOR_207080] T cells, but the risks of 
serious infection and death from prolonged immune compromise in these patients remains high9-
14. Mortality from CMV disease was 14% in a recent study of nonmyeloablative transplantation 
using HLA -haploidentical donors15. Fukuda, et al. reported an incidence of 15% invasive mo ld 
infections in nonmyeloablative transplants from HLA -matched related or unrelated donors with a 
mortality rate of 56%16. In order to reduce the toxicity of haploidentical HSCT, methods to 
selectively inhibit alloreactivity while preserving immunity to infection and the malignancy are 
clearly required17.  
Cyclophosphamide (Cy) is a highly immunosuppressive antineoplastic agent that has an 
established role in conditioning for HSCT.  Typi[INVESTIGATOR_897], the drug is administered prior to 
transpl antation to prevent graft rejection by [CONTACT_207105].  However, pre -
transplantation conditioning with Cy increases the risk of GVHD following allogeneic T cell 
infusion in mouse models18.  In contrast, administration of a prop erly timed, high dose of Cy 
after  HSCT inhibits both graft rejection and GVHD19-22.    
Based on these murine studies, investigators at Johns Hopkins University developed a non -
myeloablative conditioning regimen for transplantation of non-T cell -depleted marrow from 
partially HLA -matched, or haploidentical, bone marrow from first -degree relatives23.  This study 
demonstrated the optimal titration of post -transplantation Cy dose, given in conjunction with pre -
transplantat ion fludarabine and total body irradiation (TBI), to achieve a regimen that had an 
acceptably low risk of graft rejection and GVHD, the two major complications of haploidentical 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
[ADDRESS_246948].  All patients received mycophenolate mofetil (MMF) and tacrolimus, begin ning [ADDRESS_246949] -transplant Cy administration for GVHD prophylaxis.  A total of 88 patients with poor 
risk hematologic malignancies were studied. The median times to neutrophil and platelet 
recovery for all patients were 15 and 24 days, respectivel y. Graft failure occurred in a total of 
15/84 patients (18%). All but two patients with graft failure experienced recovery of autologous 
hematopoiesis with median times to neutrophil and platelet engraftment of 24 days (range 11 -48 
days) and 44 days (range  15-395 days), respectively.  
The cumulative incidences of grades II -IV and III -IV acute GVHD by [CONTACT_4475] 200 were 35% and 
10%. The cumulative incidence of chronic and extensive chronic GVHD in the first year after 
transplantation for the entire population was 2 2% and 14%, respectively. The cumulative 
incidences of NRM at 180 days and 1 year after transplantation were 13% and 19%, respectively. 
The cumulative incidences of relapse at 1 and 2 years after transplantation were 50% and 57%, 
respectively. At a median follow -up of survivors of 817 days (range, 112 -1808 days), the 
actuarial overall survival at 1 and 2 years were 45% and 35%, respectively. The actuarial EFS at 
1 and 2 years were 32% and 24%, respectively. Furthermore, CMV reactivation was observed in 
20 of 60 (33%) high -risk patients, and proven or probable invasive mold infections post -
transplant, all caused by [CONTACT_207106] , were observed in 6 of 88 (6.8%) patients, of whom two 
had infection prior to transplant. Two patients died from Aspergillus infect ion, one while 
persistently neutropenic following graft failure. There was no CMV -associated mortality.  
From these results, it was concluded that (1) post -transplantation immunosuppression with high 
dose Cy, tacrolimus, and MMF was associated with an accep tably low incidence of graft 
rejection, severe acute GVHD, and extensive chronic GVHD, (2) there was effective clinical 
immune reconstitution as demonstrated by [CONTACT_207107], 
and (3) relapse represented the major cau se of treatment failure.  Strategies to decrease the 
relapse risk are clearly needed.   
Clinical data from haploidentical transplantation (haplo -HSCT) has revealed that NK cells are 
responsible for remarkably favorable effects in adults with AML and more r ecently, in children 
with high -risk ALL24-27.  The emergence of the concept of NK cell alloreactivity has represented 
an important advance in the field of haplo -HSCT, underlining for the first time that not only 
adaptive immunity, but also innate immunity is a crucial element for a successful clinical 
outcome. Indeed, it has become evident that the therapeutic effect of haplo -HSCT is in part 
dependent on the graft -versus -leukemia (GVL) effect exerted by [CONTACT_207108].   
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
16 
 Each NK cell expresses one or more inhibitory receptors (KIR), which through interactions with 
self-HLA class I molecules, prevent NK cell -mediated attack against healthy, autologous cells. 
On the other hand, cells in which HLA class I expression is comprom ised (for example, after 
tumor transformation or viral infection) become susceptible to NK -mediated killing.  Thus, in an 
autologous setting, NK cells can kill only cells that do not express sufficient HLA class I 
molecules, whereas in a nonself environmen t, NK cells may kill allogeneic cells when they 
express inhibitory KIRs that are not engaged by [CONTACT_207109] I alleles present on 
allogeneic target cells. As a NK -mediated, alloreactive response depends on the failure of KIRs 
to engage their HLA cl ass I ligands, alloreactive NK cells have been said to see “missing self” on 
allogeneic target cells. Alloreactivity in haplo -HSCT is operating through the mechanism of 
missing -self recognition, provided that the donor expresses a KIR ligand that is missin g in the 
recipi[INVESTIGATOR_841]'s HLA genotype and expresses the specific inhibitory KIR, leading to a KIR/KIR ligand 
mismatch in the donor -versus -recipi[INVESTIGATOR_207081].  
A number of activating forms of KIRs (e.g., KIR2DS1, KIR2DS2, and KIR3DS1) have been 
recently describ ed, which are highly homologous in the extracellular domain to their inhibitory 
counterparts and present a short cytoplasmic tail lacking ITIM (immunoreceptor tyrosine -based 
inhibition motifs) .  Inhibitory/activating KIRs as well as HLA are two polymorphi c gene 
systems. As they are encoded on separate chromosomes, they segregate independently. Over [ADDRESS_246950] been described, which highlights the great variability in the KIR 
gene family. Combinations of HLA class I and KIR variants inf luence resistance to infections, 
susceptibility to autoimmune diseases, and complications of pregnancy, as well as outcome after 
hematopoietic stem cell transplantation.  All HLA/KIR combinations can be divided in two basic 
KIR haplotypes: group A haplotyp es, which have a fixed number of genes that encode inhibitory 
receptors (with the exception of the activating receptor KIR2DS4), and group B haplotypes, 
which have variable gene contents, including additional activating receptor genes.  Recent 
studies have  suggested that donor group B haplotypes yield significantly better protection against 
leukemic relapses, as compared with group A, and improved disease -free survival in patients 
undergoing T cell -depleted HSCT for AML28-30.  
Research has shown that NK cel l cytotoxicity can be potentiated in vitro by [CONTACT_094] -exposing tumor 
cells to the proteasome inhibitor, Bortezomib31.  Pretreatment of tumor cells with Bortezomib 
has been shown to increase NK -mediated tumor control in multiple cancer types including 
myeloma, leukemia, renal cell carcinoma, prostate cancer, breast cancer, squamous cell and 
hepatocellular carcinoma32-37.  Enhanced NK cell killing effect is in part dependent on the up -
regulation of receptors on the tumor surface for tumor necrosis factor related apoptosis inducing 
ligand (TRAIL) and to drug -induced augmentation of tumor caspase -8 activity, leading to 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
17 
 enhanced tumor killing via perforin/granzyme mediated NK -tumor cytotoxicity32.  Other 
mechanisms of action include down -regulation of class I HLA on tumor cells34, as well as 
selectively induced the expression of the tumor cells NKG2D ligands, MICA and MICB33,38.   
In animal models, systemic proteasome inhibition has been shown to significantly inhibit acute 
GVHD while preserving graft -versus -tumor (GV T) responses in advanced tumor -bearing mice 
after allogeneic BMT with no observed adverse effects on myeloid recovery and donor 
chimerism39.  Bortezomib has been shown to decrease T -helper [ADDRESS_246951] 
pathogens43.  Clinical studies utilizing a short course of bortezomib with tacrolimus/methotrexate 
for GVHD prophylaxis demonstrated low rates of GVHD in HLA -mismatched unrelated donor 
transplants, while i mproving T cell and NK cell reconstitution44. 
It is therefore hypothesized that proteasome inhibition can improve the results of haploidentical 
transplantation by [CONTACT_207110].  MLN9708 is a selective, orally bioavailable, second -generation 
proteasome inhibitor, which has a shorter proteasome dissociation half -life and improved 
pharmacokinetics, pharmacodynamics, and antitumor activity compared with bortezomib.  In 
clinical studies of patients with myleoma, MLN9708 has shown comparable clinical activity and 
a better safety profile when compared to bortezomib45.  Benefits of MLN9708 include the 
convenience of once weekly oral fixed dosing as well as a significantly decreased r isk of 
peripheral neuropathy, which is one of the biggest impediment to long -term administration of 
bortezomib.  We further hypothesize that the combination of tacrolimus and MLN9708 will 
provide sufficient GVHD prophylaxis making it possible to eliminate the need for 
mycophenolate mofetil, which has been shown to significantly decrease NK cell proliferation 
and cytotoxic function46. 
1.1.[ADDRESS_246952] indication for nonmyeloablative 
haploidentical t ransplantation includ e acute lymphoblastic leukemia/lymphoma in complete 
remission, acute myeloid leukemia in complete remission, relapsed Burkitt leukemia/lymphoma 
in complete remission, multiple myeloma (relapsed disease and/or presence of del17p), relap sed 
lymphoma including marginal zone, follicular, and chemotherapy -sensitive diffuse large B cell, 
T cell, Mantle cell, and Hodgkin’s . Specific disease criteria are listed in section 5.1 Inclusion 
Criteria.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
18 
 1.1.2          MLN9708   
1.2    Preclinical Experience  
Please refer to the current MLN9708 Investigator’s Brochure (IB) and Safety Management 
Attachment (SMA).  
1.[ADDRESS_246953] been treated with MLN9708 across 9 enrolling, sponsor -
led phase 1 or phase 1/2 studies evalu ating both twice -weekly and weekly dosing schedules.  
MLN9708 is available as an intravenous and oral formulation. Regardless of the route of 
administration in the twice -weekly dosing schedule, MLN9708 is given on Days 1, 4, 8, and 11 
of a 21 -day cycle; in  the weekly dosing schedule, the drug is given on Days 1, 8, and 15 of a 28 -
day cycle.  To date, the development of oral MLN9708 has focused on multiple myeloma 
[relapsed and/or refractory and newly diagnosed] and a different yet related plasma cell 
dyscras ia, systemic light chain (AL) amyloidosis. A clinical pharmacology study looking at 
drug-drug interactions  (DDIs) , the effect of food, and bioavailability also uses the oral 
formulation. Details of these trials can be found in ClinicalTrials.gov and the ML N9708 IB.    
1.4   Pharmacokinetics and Drug Metabolism  
Clinical IV and PO pharmacokinetic (PK) data show that MLN9708 (measured as the 
biologically active boronic acid form of MLN9708 [MLN2238]) has multi -exponential 
disposition with a rapid initial phase tha t is largely over by [ADDRESS_246954] maximum plasma concentration (T max) of approximately 0.5 
to 2.0 hours and terminal t 1/2 after multiple dosi ng of approximately 5 to 7 days47. Results of a 
populatio n PK analysis (N = 137) show that there is no relationship between body surface area 
(BSA) or body weight and clearance (CL).  Also, based on stochastic simulations for fixed dose, 
exposures are independent of the individual patient’s BSA48.  Based on thes e data, a 
recommendation was made for fixed dosing in clinical trials.  An absolute bioavailability of 67% 
was determined for MLN9708 using the population PK analysis.  See the IB for information on 
the PK for IV doses of MLN9708.  
Metabolism appears to be the major route of elimination for MLN9708, with negligible urinary 
excretion of the parent drug (<  3% of dose).  In vitro studies of liver microsomes show that 
MLN9708 is metabolized by [CONTACT_20550] P450 enzymes (CYPs) and non -CYP 
enzymes/proteins.   The rank order of relative biotransformation activity of the 5 major human 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
19 
 CYP isozymes is 3A4 (34.2%) >  1A2 (30.7%) > 2D6 (14.7%) >  2C9 (12.1%) >  2C19 (<  1%).  
MLN9708 is not an inhibitor of CYPs 1A2, 2C9, 2C19, 2D6, or 3A4, nor is it a time -dependent 
inhibitor of CYP3A4/5.  The potential for MLN9708 treatment to produce DDIs via CYP 
inhibition is inferred to be low; however, there may be a potential for DDIs with a concomitant 
strong CYP3A4 or CYP1A2 inhibitor because of the potential for first -pass met abolism when 
MLN9708 is administered via the PO route and because of the moderate contribution of 
CYP3A4 - and CYP1A2 -mediated metabolism of MLN9708 in human liver microsomes.  
MLN9708 may be a weak substrate of P -glycoprotein (P -gp), breast cancer resistan ce protein 
(BCRP), and multidrug resistance associated protein (MRP2) efflux pump transporters.  
MLN9708 is not an inhibitor of P -gp, BCRP, and MRP2.  The potential for DDIs with substrates 
or inhibitors of P -gp, BCRP, and MRP2 is, therefore, inferred to b e low.  
1.5    Clinical Trial Experience Using the Oral Formulation of MLN9708  
In the 7 studies actively enrolling patients to investigate oral MLN9708 in patients with differin g 
malignancies (multiple myeloma, AL amyloidosis, nonhematologic cancers, and lymph oma), a 
total of [ADDRESS_246955] been treated with 
different doses of MLN9708, either as a single agent treatment or in combination with currently 
clinically available treatments. Information regardin g the ongoing studies, patient populations, 
and doses investigated are included  in Table 1 -1. 
 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
20 
 Table  1-1   Ongoing Studies of Oral MLN9708  
Trial/  
Population  Description  Doses Investigated  
C16003  
RRMM  
N = 58 PO, twice weekly (TW), single agent  0.24-2.23 m g/m2, TW  
MTD:  2.0 mg/m2 
DLT:  rash, thrombocytopenia  
C16004  
RRMM  
N = 52 PO, weekly (W), single agent  0.24-3.95 mg/m2, W 
MTD:  2.97 mg/m2 
DLT:  rash, nausea, vomiting , diarrhea  
C16005  
NDMM  
N = 65 PO, W, combination with LenDex  
28 day cycle  1.68-3.95 mg/m2, W 
MTD:  2.97 mg/m2 
DLT:  nausea, vomiting, diarrhea, syncope  
RP2D*:  4.0 mg fixed (switch ed to fixed dosing in 
phase 2 , relevant to 2.23 mg/m2) 
C16006  
NDMM  
N = 28 PO, TW (Arm A - 42 day cycle ) and W 
(Arm B - 28 day cycle ), combination 
with melphalan and prednisone  Arm A*:  3 -3.7 mg, fixed dose, TW  
DLT: rash, thrombocytopenia, subileus  
Arm B*:  5.5 mg , fixed dose, W  
DLT: Esophageal ulcer  
C16007  
RRAL  
N = 6  PO, W, single agent  4-5.5 mg, fixed dose*, W  
MTD: 4 mg  
DLT: thrombocytopenia, dirrhea, dyspnea, acute  
rise in creatinine, cardiac arrest  
 
C16008  
NDMM  
N=11  PO, TW, combination with LenDex 21 
day cycle  3.0-3.7 mg fixed dose* W  
MTD: 4 mg  
 
C16009  
Solid 
tumors, 
Lymphomas  
N = 22  PO, W, single agent  5.5 mg fixed dose* W  
C16010  
RRMM  
N = 1  PO, W, combination wi th LenDex  4.0 mg fixed dose* W  
TB-
MC010034  
RRMM  
N = 5  PO, W, single agent in 1s part of study 
then in combination with LenDex in 2nd 
part 3.0 mg fixed dose* W  
DLT: thrombocytopenia, nausea, hypertension, 
diarrhea  
Abbreviations:  RRAL = Relapsed or refrac tory Primary systemic light chain (AL) amyloidosis; BSA = body 
surface area  ; DLT = dose -limiting toxicity; IV = intravenuously; LenDex = lenalidomide plus 
dexamethasone; MTD = maximum tolerated dose; NDMM = newly diagnosed multiple myeloma; PO = 
orally; R RMM = relapsed and/or refractory multiple myeloma ; RP2D = recommended phase 2 dose  
* Approximate body surface area (BSA) and fixed dosing equivalence:  3 mg ~ equivalent to 1.68 mg/m2 
BSA dosing; 4.0 mg ~ equivalent to 2.23 mg/m2 BSA dosing; and 5.5 mg ~ e quivalent to 2.97 mg/m2 BSA 
dosing.  
 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
[ADDRESS_246956] supportive care. From 
experience from phase 1 through 2 studies the major toxicities can be managed to allow repeat 
treatment cycles over periods extending beyond 24 months.  
In the 4 ongoing studies (C16003, C16004, C16007, and C16009) investigating single -agent oral 
MLN9708 in patients with differing malignancies (multiple myeloma, AL amyloidosis, 
nonhematologic cancers, and lymphoma), a total of [ADDRESS_246957] frequent (at least 10%) AEs occurring in the pooled safety  
population from single -agent oral MLN9708 Studies (C16003 , C16004, C16007, and C16009) i s 
shown in Table [ADDRESS_246958] Common (At Least 10% of Total) All Grade Treatment -
Emergent Adverse Events (Oral MLN9708 Single -Agent [C16003/4/7/9] 
Safety Population)  
Primary System Organ Class  Preferred Ter m and Incidence  
N=146  
n (%)  
Subjects with at Least One Adverse Event 135 (92)   
Gastrointestinal disorders 102 (70)  Nausea 68 (47); Diarrhoea 55 (38); Vomiting 51 (35); 
Abdominal pain 21 (14); Constipation 21 (14)  
General disorders and administration sit e conditions 98 
(67) Fatigue 71 (49); Pyrexia 31 (21); Oedema peripheral 15 
(10) 
Blood and lymphatic system disorders 77 (53)  Thrombocytopenia 60 (41); Anaemia 30 (21); 
Neutropenia 23 (16); Leukopenia 15 (10)  
Nervous system disorders 63 (43)  Headache 20 (14); Dizziness 18 (12)  
Metabolism and nutrition disorders 60 (41)  Decreased appetite 39 (27) Dehydration 21 (14)  
Respi[INVESTIGATOR_696], thoracic and mediastinal disorders 60 (41)  Cough 22 (15); Dyspnoea 21 (14)  
Skin and subcutaneous tissue disorders 60 (41)  Rash  macular 17 (12)  
Musculoskeletal and connective tissue disorders 56 
(38) Arthralgia 20 (14); Back pain 17 (12)  
Infections and infestations 54 (37)  Upper respi[INVESTIGATOR_1092] 21 (14)  
Source: MLN9708 Investigator’s Brochure Edition [ADDRESS_246959] Incidence: A subject counts once for each preferred term. Percentages use the number of treated subjects as 
the denominator  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
[ADDRESS_246960] been tr eated with different 
doses of MLN9708 in combination with lenalidomide and dexamethasone in 2 trials (C16005 
and C16008) and with melphalan and prednisone in 1 trial (C16006). The most frequent (at least 
10%) adverse events occurring in the pooled safety p opulation from Studies C16005, C16006, 
and C16008 is shown in Table [ADDRESS_246961] Common (At L east 10% of Total) Treatment - Emergent 
Adverse Events (Oral MLN9708 Combination Agent [C16005/6/8] Safety 
Population)  
 
Primary System Organ Class  Preferred Term and Incidence  
N= 96 n (%)  
Subjects with at Least One Adverse Event 135 (92)    
Gastrointestin al disorders 70 (73)  Nausea 32 (33); Constipation 29 (30); Vomiting 25 (26)  
Diarrhoea 22 (23)  
General disorders and administration site conditions 64 
(67) Fatigue 37 (39); Oedema peripheral 20 (21); Pyrexia 19 
(20) 
Skin and subcutaneous tissue disorders 57 (59)  Rash 13 (14)  
Nervous system disorders 46 (48)  Neuropathy peripheral 13 (14); Dysgeusia 12 (13)  
Dizziness 11 (11)  
Musculoskeletal and connective tissue disorders 45 
(47) Back pain 18 (19); Muscle spasms 10 (10)  
Blood and lymphatic system disorder s 42 (44)  Thrombocytopenia 28 (29); Anaemia 22 (23);  
Neutropenia 19 (20)  
Infections and infestations 40 (42)  Upper respi[INVESTIGATOR_1092] 17 (18);  
Metabolism and nutrition disorders 38 (40)  Decreased appetite 11 (11)  
Respi[INVESTIGATOR_696], thoracic and med iastinal disorders 34 (35)  Dyspnoea 13 (14); Cough 11 (11)  
Psychiatric disorders 23 (24)  Insomnia 15 (16)  
Source: MLN9708 Investigator’s Brochure Edition [ADDRESS_246962] Incidence: A subject counts once for each preferred term. Percentages use the number of treated  subjects as 
the denominator.  
 
The clinical experience with MLN9708 also shows early signs of antitumor activity as  evide nced 
by [CONTACT_2669] a 50% reduction in disease burden in some patients and prolonged  disease 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
23 
 stabilization in others across all ongoing trials. The antitumor activity has been seen  with single -
agent MLN9708, when combined with established therapi[INVESTIGATOR_014], and acros s the malignancies studied 
(advanced solid tumors49, non -Hodgkin ’s disease, Hodgkin ’s disease50, relapsed and/or 
refractory multiple myeloma [RRMM ; 51,52], relapsed or refractory systemic light  chain 
amyloidosis [RRAL ; 53], and newly diagnosed multiple mye loma [NDMM ; 54-56] to date.  
Though additional data are needed to characterize the clinical benefit of this drug, the  emerging 
data supports the ongoing development of MLN9708.  
Of particular relevance to this study (C16011) is the clinical experience from S tudies  C16004 
and C16007 in which single -agent MLN9708 is administered weekly in patients  with RRMM or 
RRAL, respectively.  
1.6    Relapsed and/or Refractory Multiple Myeloma  
Study C16004 is an open -label, dose -escalation, phase [ADDRESS_246963] included bortezomib, tha lidomide (or lenalidomide), and 
corticosteroids. The dose -escalation phase of the trial has completed. In this study, 2 of 3  patients 
experienced protocol -defined DLTs (Grade 3 ras h and Grade 3 nausea, vomiting, and diarrhea) 
at a dose of 3.95 mg/m2. As per protocol, s ubsequent patients were treated at  1 dose level below 
(2.97mg/m2) where 1 of 6 patients experienced a DLT (Grade 3 nausea,  vomiting, and diarrhea). 
The MTD of weekly oral MLN9708 was determined to be  2.97 mg/m2.  
Once the MTD was established, cohorts of pat ients representing the heterogeneous patient  
population currently seen in clinical practice were enrolled i n order to further evaluate the safety, 
tolerability, efficacy, PK, and pharmacodynamics of ora l MLN9708. The MTD expansion 
cohorts enrolling are:  
1. Relapsed and Refractory expansion cohort [r efractory is defined as disease progression 
while on therapy or within [ADDRESS_246964] dose of therapy];  
2. Carfilzomib expansion cohort  
3. Proteasome Inhibitor -Naïve expansion cohort  
4. VELCADE -Relapsed expansion coh ort 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
[ADDRESS_246965]  
MLN9708 has antitumor activity in heavily pretr eated MM patients, with durable 
responses/disease control, and is generally well tolerated57, 58. 
As of the 30 Apr il 2012 data cut, these patients are considered heavily pretreated as evidenced by 
a median number of 4 (range 1 –13) prior lines of therapy, with 66% refractory to the last line of 
therapy. Patients have received a median of 2 cycles of therapy (range, 1 - 11). Five patients have 
achieved objective response: 1 patient achieved a VGPR and 4 patients achieved a PR. 
Additionally, 15 patients achieved durable disease stabilization for up to 9.5 months. At data cut -
off, 15 patients remain on treatment; discontinu ation of treatment was primarily due to 
progressive disease (69%).  
A summary of the safety profile of patients treated in Study C16004 is outlined in Table 1 -4. 
Overall, 92% of patients experienced a TEAE of any grade and of any cause. Peripheral  
neuropath y was limited to Grade 1/ 2 in 6 patients, with 3 patients reporting baseline Grade 1 PN 
at study entry.  
 
Table 1-4    Study C1600 4, Oral MLN9708, Single Agent, Given Weekly :  Most 
Common TEAEs as of 30 April 12  (N= 52) 
Most Common (> 20%) Any Grade and I rrespective 
of Cause  Thrombocytopenia ( 54%) 
Fatigue (48%)  
Nausea ( 44%), diarrhea ( 44%) 
Vomiting ( 37%) 
Decreased appetite  (33%) 
Rash* (31%)  
Anemia  (25%) 
Neutropenia ( 23%) 
Drug -Related Grade  3 in > 5% of patients  
 Thrombocytopenia ( 38%) 
Diarrhea and neutr openia 17% (each), fatigue and 
lymphopenia 10% (each), nausea and decreased 
appetite 8% (each) and vomiting 6%  
 
Source: MLN9708 Investigator’s Brochure Edition 6  
* Rash includes preferred terms of rash macular, rash, maculo -papular, rash morbilliform, ras h pruritic,  
pruritus,, rash erythematous, exfoliative rash, and rash popular  
 
Dose reductions required were due to AEs that included rash, neutropenia, thrombocytopenia, 
diarrhea, nausea, vomiting, dehydration, hypotension, increase in serum creatinine, a bdominal 
pain, ileus, fatigue, and pneumonia. The AEs reported for the 5 patients who were required to 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
25 
 discontinue treatment included Grade 2 MLN9708 -related nausea/vomiting in 1 patient treated 
above the MTD, Grade 3 MLN9708 -related diarrhea in a second p atient, related Grade 3 
thrombocytopenia, related Grade 2 dyspnea, and not  related Grade 4 elevation in creatinine  (1 
patient each). There were no on -study deaths.  
Study C16007 is evaluating single agent weekly , Day 1, 8, and [ADDRESS_246966] 1 prior therapy. The objectives of this study are to determine 
the safety, tolerability, and MTD, as well as to determine hematologic and organ response rates 
in this patient population. The starting dose level wa s selected from Study C16004 as previously 
described. In Study C16007 the dose was switched from the BSA -based dosing to the fixed dose, 
thereby [CONTACT_941] 4.0 mg fixed starting dose in Study C16007 corresponds to the 2.23 mg/m2 dose (one 
dose level below MTD) fr om Study C16004. This study is currently enrolling patients in the 
dose-expansion portion of the trial.  
As of [ADDRESS_246967] dose level of 4.0 mg, 
1 of 6 patients experienced a protocol -defined DLT (that is, thrombocytopenia that lasted more 
than 2 weeks, which met the definition of a DLT due to the delay in starting Cycle 2). As per 
protocol, the dose was escalated to 5.5 mg for the next cohort of patients where 2 of 5 patients 
experienced a DLT (Gr ade 3 diarrhea, n=1; and Grade [ADDRESS_246968], n=1). The latter patient did not appear to have cardiac AL 
amyloidosis by [CONTACT_207111], but did have substantial renal involvemen t. After 
the occurrence of this DLT, diagnoses included cardiac involvement and CHF. The MTD of 
weekly oral MLN9708 was determined to be 4.0 mg. Following the establishment of the MTD, 
patients are currently being enrolled in to 1 of 2 cohorts: proteasome inhibitor naïve or 
proteasome inhibitor exposed59. 
As of the 30 April 2012 data cut, the patients enrolled in the study are considered heavily 
pretreated, as evidenced by a median number of 3 prior lines of therapy (range 1 –7), with 38% 
and 46% of patients  having been previously treated with bortezomib and lenalidomide, 
respectively. To be eligible for the study, patients must have amyloid involvement of the heart, 
kidney, or both; at the data cut the organ involvement distribution was 6, 4, and [ADDRESS_246969] received a median of 2.5 cycles of therapy (range, 1 -12). Eight 
patients remain on treatment. Early signs of activity have been reported. There were  [ADDRESS_246970] 1 cycle of therapy with completed respo nse assessments (9 in the 4.0 
mg [MTD] cohort and 2 in the 5.5 mg cohort). The overall  hematologic response rate at MTD is 
56% (5 patients achieved a hematologic response [4  VGPR and 1 PR]; 3 patients showed no 
change, and 1 patient had an early progressio n.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
26 
 A summary of the safety profile of patients treated in Study C16007 is outlined in Table 1 -5. 
Overall, 86% of patients experienced a TEAE of any grade and of any cause.  
Table 1-[ADDRESS_246971] 
Common T EAEs as of 30April 12  (N = 14) 
Most Common (> 20%)  
Any Grade and Irrespective of Cause  Nausea (50%)  
Fatigue ( 36%) 
Thrombocytopenia ( 29%) 
Diarrhea ( 29%) 
Decreased Appetite (21%)  
Peripheral Edema (21%)  
Dyspnea (21%)  
Abdominal pain (21%)  
Drug -Related Grade  3 in more than 3 Patients  Thrombocytopenia 5 patients, rash 3 patients, 
dehydration 2 patients, fatigue 2 patients  
 
Source: MLN9708 Investigator’s Brochure Edition 6  
 
One patient discontinued study drug administration due to a TEAE (patient with DLT of a cute 
rise in serum creatinine, dyspnea, and cardiac arrest treated at 5.5 mg, as noted above). No death 
has been reported.  
The potential risks reported with MLN9708 use, pooled from all studies using the oral 
formulations, were anticipated based on preclin ical data and previous experience with 
VELCADE and are noted in the MLN9708 IB, SMA, and ICF documents. Regardless of whether 
MLN9708 is administered on the once weekly or twice weekly dosing schedule, there is 
consistency among the type of TEAEs reported,  despi[INVESTIGATOR_207082]. While the predominant potential toxicities may be severe in some 
cases, they are largely reversible, and can be managed by [CONTACT_207112], which may include dose reductions and supportive care. Please 
refer to the MLN9708 IB and SMA for further information.  
1.7    Newly Diagnosed Multiple Myeloma (NDMM)  
In Study C16005, MLN9708 is given weekly (Days 1, 8, and 15), in combination with 
lenalidomide (Days 1 -21), and dexamethasone (Days 1, 8, 15, and 22) in a 28 -day cycle.  
Enroll ment to this study is closed.   
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
27 
 Clinical data as of 30 April 2012 is available.  The MTD in Study C16005 was determined to be  
2.97 mg/m2 given weekly in a 28 -day cycle with LenDex.  The DLTs were urticarial rash, 
dizziness, nausea, orthostatic hypotension, vomiting, diarrhoea , and syncope.  The recommended 
phase 2 dose (RP 2D) estimation was established following evaluation of the available data from 
the phase 1 por tion of the trial which included, but was not limited to, analyses of efficacy results 
and adverse events (Grade 3/4 AEs, SAEs, all grades peripheral neuropathy, and treatment 
discontinuation).  Given that the dose of MLN9708 at 2.97 mg/m2 compromised the maximal 
dosing of lenalidomide and that the dose of 2.23 mg/m2 is very tolerable and clinically active, 
Millennium designated 2.23 mg/m2 as the RP2D after evaluation of the data and discussion with 
investigators.  The RP2D of 2.23 mg/m2 has been translated  into a fixed dose of 4.0 mg based on 
the results from the population PK analysis.   Enrollment in this study has been completed; final 
study results are not available, but preliminary data suggests oral MLN9708 given weekly plus 
lenalidomide and dexamethas one in a 28 -day cycle appears well tolerated with manageable 
toxicity and encouraging antitumor activity.   
In Study C16005, 15 of 15 (100%) patients in the dose escalation portion of the study 
experienced at least 1 TEAE irrespective of grade or causality .  At the MTD across all dose 
expansion cohorts 49 of 53 patients (including 3 patients from the dose escalation cohort [92%]) 
reported at least [ADDRESS_246972] common AE reported (38%).  Other common AEs reported include nausea (32%), 
constipation (30%), upper respi[INVESTIGATOR_4416] (23%), and peripheral oedema  (21%).  Skin 
toxicity, primarily erythematous rash, occurred in 62% of patients (of note, rash is an 
overlappi[INVESTIGATOR_207083] 9708 and lenalidomide).  Peripheral neuropathy was reported in 
13% of patients; Grade 3 in 1 patient.   
A summary of the overall safety profile of patients treated in Study C16005 is outlined in  Table 
1-6.  Overall, 100% of [ADDRESS_246973]  one TEAE of any grade and of any cause.   
Table 1-6    Study C16005:  Oral MLN9708 Given Weekly in Combination With 
Lenalidomide and Dexamethasone, Most Common TEAEs as of [ADDRESS_246974] Common (>  20%) Any Grade and Irrespective of 
Cause  Fatigue (37% ) 
Nausea (34%)  
Constipation (31%)  
Vomiting (28%)  
Diarrhoea (26%)  
Thrombocytopenia (23%)  
Upper respi[INVESTIGATOR_1092] (22%)  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
28 
 Anaemia and oedema peripheral ( 20% each)  
Drug -Relateda Grade  3 in  2 Patients  Nausea, vomiting (n=3 each)  
Thrombocytopeni a, lymphopenia, rash pruritic (n=2 each )  
 
Source: MLN9708 Investigator’s Brochure Edition [ADDRESS_246975] common drug -related SAEs reported in Study C16005 a s of 30 April 2012  include 
pneumonia, in fection, d iverticulitis , localised infection , gastrointestinal haemorrhage , respi[INVESTIGATOR_14256] (RSV) pneumonia f aecaloma , pyrexia,  pneumonia respi[INVESTIGATOR_207084] , 
non-cardiac chest pain, peripheral oedma, asthenia, h yponatraemia vomiting, diarrhoea , nausea, 
chest pain, dehydration, anemia, dizziness, peripheral sensory neuropathy, orthostatic 
hypotension, embolism, muscular weakness, acute renal failure, blood creatinine increased, 
maculopapular rash, atrial fibrillation , syncope, hypotensio n, and deep vein thrombosis, and back 
pain.   
As of the clinical data cutoff, [ADDRESS_246976] discontinued treatment due to TEAEs including 
gastrointestinal hemorrhage , angioedema , syncope, and RSV pneumonia.  
One death was reported for a patient with RSV pneumonia; the event was deemed by [CONTACT_207113]9708.   
1.[ADDRESS_246977] of NK cell alloreactivity seen in HLA -
mismatched transplantation. These strategies include (1) choosing potential haploidentical 
donors for optimal NK -alloreactivity, (2) ut ilizing proteasome inhibition post -transplant with 
MLN9708 to both sensitize tumor cells to NK cytotoxicity and protect against graft -versus -host 
disease (GVHD), and (3) eliminating mycophenolate mofetil from the post -transplant 
immunosuppression regimen t o improve NK cell reconstitution following haploidentical 
peripheral blood stem cell transplantation.  
Patients will receive a nonmyeloablative haploidentical transplant using a T -cell replete allograft 
and post -transplant cyclophosphamide as previously des cribed at our center (Bashey et al. J Clin 
Oncol. 2013; 31(10):1310 -6).  MLN9708 will be administered once weekly  for [ADDRESS_246978] of 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
29 
 tacrolimus only (MLN9708 will su bstitute for mycophenolate mofetil as the second GVHD 
prophylactic medication).  
1.9    Potential Risks and Benefits  
MLN9708  
Please refer to the current MLN9708 Investigator’s Brochure (IB) and Safety Management 
Attachment (SMA).  
MLN9708 is a modified dipeptid e boronic acid proteasome inhibitor similar to VELCADE,  
which has a known safety profile  [VELCADE PI] . The most frequent AEs reported to date in the 
ongoing  MLN9708 phase [ADDRESS_246979] a 50% reduction in 
disease burden in some patients and prolonged disease stabilization in others across all ongoing 
trials49,50,51,52,54,55,56. 
This study will be conducted in compliance with the protocol, good clinical practice (GCP),  
applicable regulatory requirements, and International Co nference on Harmonisation (ICH) 
guidelines.  
Cyclophosphamide (Cytoxan®)  
Cyclophosphamide is an alkylating agent  which prevents cell division primarily by [CONTACT_12783] -linking 
DNA strands. Cyclophosphamide is cell cycle nonspecific. Cyclophosphamide for injection is 
available in 500mg, 1gram, and [ADDRESS_246980] is 20 mg/ml. The calculated dose 
will be diluted further in 500 -1000  ml of Dextrose 5%  in water  or NS . Each dose will be infused 
over 1 -2 hr (depending on the total volume). Clinical toxicities of cyclophos phamide include 
alopecia, nausea and vomiting, headache and dizziness, hemorrhagic cystitis, cardiotoxicity, 
immunosuppression, myelosuppression, pulmonary fibrosis, increased hepatic enzymes and 
syndrome of inappropriate anti -diuretic hormone (SIADH).  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
30 
 Mesna (sodium -2-mercapto ethane sulphonate)  
Mesna is a prophylactic agent used to prevent hemorrhagic cystitis induced by [CONTACT_12785] (cyclophosphamide and ifosphamide). It has no intrinsic cytotoxicity and no 
antagonistic effects on chemotherapy. Mesna binds with acrolein, the urotoxic metabolite 
produced by [CONTACT_12786], to produce a non -toxic thioether and slows the rate of 
acrolein formation by [CONTACT_12787] 4 -hydroxy metabolites of oxasophosphorines. Mesna is 
available in 1000 mg vial s containing a 100 mg/ml solution. Mesna will be diluted and 
administered per  institutional standards. Mesna will be utilized per standard of care for the day [ADDRESS_246981] transplant cyclophosphamide doses, not for the pre -transplant doses . At the dose s 
used for uroprotection mesna is virtually non -toxic. However, adverse effects which may be 
attributable to mesna include nausea and vomiting, diarrhea, abdominal pain, altered taste, rash, 
urticaria, headache, joint or limb pain, hypotension and fatigue.   
Fludarabine (Fludara®)  
Fludarabine phosphate is purine antimetabolite that, after administration, undergoes rapid 
conversion in plasma to the nucleoside 2 -fluoro ara -A (F-araA). F -araA subsequently enters cells 
where it is phosphorylated to F -araATP and the monophosphate F -araAMP.  Once activated, F -
araATP inhibits DNA polymerase and ribonucleotide reductase. The monophosphate F -araAMP, 
once incorporated into DNA, is an effective DNA chain terminator. Fludarabine monophosphate, 
50 mg/vial, is reconstitute d with 2 ml of sterile water, resulting in a 25mg/ml solution. The 
desired dose is further diluted to concentrations of 0.04 -1 mg/ml in normal saline or 5% dextrose 
(50-100ml) for injection and will be administered by [CONTACT_12781] 30 minutes. Following  IV 
administration, the drug is metabolized to 2 -F-araA and widely distributed in tissues.  2 -F-araA 
is excreted primarily in urine and has a terminal elimination half -life of 7 to 12 hours. Clinical 
toxicities of fludarabine monophosphate include: myelosu ppression, primarily lymphopenia and 
granulocytopenia, alopecia, rash, dermatitis, nausea, vomiting, anorexia, stomatitis, diarrhea, 
somnolence, fatigue, peripheral neuropathy, mental status changes, cortical blindness, 
hepatocellular toxicity with elevati on in serum transaminases, and interstitial pneumonitis. These 
effects are reversible when the drug is discontinued.  
Tacrolimus  
Tacrolimus, also known as FK -506, is a macrolide immunosuppressant. It inhibits lymphocytes 
by [CONTACT_12789] a complex with FKBP -12, calcium, and calmodulin, leading to the decrease in the 
phosphatase activity of calcineurin. This drug is used with corticosteroids for prophylaxis of 
organ rejection in patients receiving allogeneic liver , kidney, or heart  transplants. Its use is also 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
31 
 currently being investigated in bone marrow, pancreas, pancreatic islet cell and small bowel 
transplantation. This drug is well -absorbed orally. Tacrolimus is extensively metabolized by [CONTACT_207114] -function oxidase system, primary the cytochrome P450 system (CYP3A). A metabolic 
pathway leading to the formation of [ADDRESS_246982] of the body at the level of the 
umbilicus.  The dose uniformity as measured by [CONTACT_207115] (umbilicus) is 
kept within + 10% of the prescribed dose.   An interruption in the radiotherapy regimen shoul d 
only be considered if the patient has developed potentially life threatening complications that 
preclude continuation of the radiotherapy schedule.   The dose rate will be less than 10cGy/min at 
the prescription point and should be   recorded for each tre atment as well as the total time of the 
treatment in order to compute the effective dose rate per treatment field.   
Graft Failure  
A risk of participating in this research protocol is that shifting part of the standard HSCT dose of 
cyclophosphamide after th e graft infusion may damage the graft. The consequences of damaging 
the graft may include delayed hematologic recovery  or graft failure. The risk of delayed 
hematologic recovery does not appear to be severe, based on prior experience with 
nonmyeloablative haploidentical transplantation . However, the risks of delayed hematologic 
recovery in this study cannot be directly extrapolated from referenced studies due to the 
inclusion of the investigational drug, MLN9708,  in this protocol. Primary graft failure in t he 
setting of a nonmyeloablative preparative regimen is usually not a fatal complication , as 
autologous hematopoietic recovery is usually expected .  
 
Acute and Chronic GVHD  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
32 
 The second major risk in participating in this research protocol is the risk of dev elopi[INVESTIGATOR_207085]/or chronic GVHD. The degree of GVHD varies from mild cutaneous reactions to extensive 
widespread and systemic involvement of skin, liver, and gastrointestinal tract.  The incidence of 
fatal infection is greater in patients developi[INVESTIGATOR_207086]. The development of grade 3 or higher acute GVHD is 
considered clinically significant and associated with increased morbidity and non -relapse 
mortality. The likelihood of surviving severe GVHD is to a large part dependent on the age of 
the patient and the patient’s overall condition. For the majority of the patients eligible for this 
trial who have high -risk hematologic malignancies, a moderate increase in GVHD may be 
accompanied by [CONTACT_207116] -versus -malignancy (GVM) benefit, so that the same long -
term relapse free survival is maintained.  
Regimen -related toxicities  
Toxicities directly related to the administration of high -dose chemotherapy and TBI include 
gastrointestinal to xicity (nausea, vomiting, mucositis), alopecia, infertility (which may be 
permanent), interstitial pneumonitis, idiopathic cardiomyopathy, hemorrhagic cystitis, hepatic 
venoocclusive disease, or multi -organ failure which may be fatal.  
Infection  
Infection i s a major cause of morbidity in allo HSCT and is a major concern in these patients.  
Infections may be bacterial, viral, parasitic, or fungal.  Often, these infections are life -
threatening, particularly when caused by [CONTACT_207117], and are ass ociated with high 
mortality in the transplant population.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
33 
 2.    STUDY OBJECTIVES  
 
2.1    Primary  Objectives  
 To estimate the incidence of relapse/progressi on at one -year post -transplant.  
2.2    Secondary Objectives  
 To obtain estimates of overall survival (OS), ev ent-free survival (EFS), non -relapse 
mortality (NRM), engraftment, acute and chronic graft -versus -host disease (GVHD).  
 Characterize additional hematologic and non -hematologic toxicities of MLN [ADDRESS_246983] haploidentical transplant.  
 Characterize don or hematopoietic chimerism in peripheral blood at days ~30, ~60, and 
~[ADDRESS_246984].  
3.    STUDY ENDPOINTS  
3.1    Primary Endpoints   
 Relapse/Progression  
3.2    Secondary Endpoints  
 OS, EFS, NRM , engraftment, acute and chr onic GVHD  
 Unexpected toxicities attributable  to MLN9708   
 Donor hematopoietic chimerism  
4.    STUDY DESIGN  
4.[ADDRESS_246985] -transplant care.  At a minimum, patient s will need to be seen for 
study related purposes according to the following  schedule. O ther tests and exams will be done 
according to physician  preference.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
[ADDRESS_246986] Screen  Month 1 
(4 
weekly 
visits ) Month 
2 (4 
weekly 
visit)  Month 
3 (4 
weekly 
visits)  Month 
4 Month 
5 Month 
6 Month s 
7-11 Month 
12 End of 
Study  Months 
18, 24 
and 36  
H & P  X X X X X X X X X X X 
CBC with 
differential  X X X X X X X X X X X 
Chemistry  X X X X X X X X X X X 
PFT*  X           
ECHO*  X           
IDMs 
including 
Hepatitis & 
HIV*  X           
Pregnancy test 
**(FOCBP)  X           
GVHD 
assessment   X X X X X X X X X X 
Toxicity 
Assessment   X X X X X X X X X X 
Bone marrow 
biopsy & 
aspi[INVESTIGATOR_337]     X   X   X X X 
CT/PET for 
NHL/HD for 
disease 
assessment     X   X   X X X 
Research 
Sample ***  X X (Day 
30) X (Day 
60) X (Day 
90)   X  X   
Survival            X 
New 
malignancy 
assessment            X 
 
*Testing that is done for transplant is acceptable if done within 6 weeks of the start of study drug.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
35 
 **Women with a uterus <50 or women >50 but < one year without a menstrual cycle) are considered 
FOCBP.  
*** Research samples will be collected for lymphocyte subsets.  Additional PBMCs will be collected 
to be frozen for future immune reconstitution studies. Approximately 30 -50ml of blood will be 
collected  at each time point.     
 
MLN9708 will be given weekly x  3 weeks every 28 day cycles , for up to 12 cycles starting at 
D+[ADDRESS_246987] -transplant.   
4.2    Number of Patient s 
Twenty -five (25) patients will be enrolled on this study .  Should a patient sign consent and either 
not be transplanted or elect not to start MLN9708, they will be considered a screen failure .  
Patients who have begun high dose chemotherapy and decide not to start MLN9708 will be 
placed on mycophenolate mofetil 15 mg/kg actual body weight orally t hree times daily 
(maximum total daily dose of 3 grams) through day +[ADDRESS_246988] meet all of the following inclusion criteria to be enrolled in the study:  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
36 
 1. Availability of a 3/6 – 5/6 matched (HLA -A, B, DR) related donor   
 Donor must have negative HLA cross -match in the host vs. graft dir ection.  
 Donor must be willing to donate mobilized peripheral blood stem cells  
2. Male or female patients Age ≥ 18 years  
3. Karnofsky status ≥  70% *(Appendix 1)  
4. Voluntary written consent must be given before performance of any study related procedure 
not part of standard medical care, with the understanding that consent may be withdrawn by 
[CONTACT_207118].  
5. One of the following high -risk malignancies:  
Chronic Myelogenous Leukemia  
 Chronic myelogenous leukemia in chronic phase, resistant  and/or intolerant to 
tyrosine kinase inhibitors (OR)  
 Chronic myelogenous leukemia in a ccelerated phase (OR)  
 Chronic myelogenous leukemia with blast crisis that has entered into a second 
chronic phase following induction chemotherapy.   
Acute Myelogenous Leukemia  
 2nd or subsequent complete remission (OR)  
 Primary induction chemotherapy failur e, but subsequently entered into a complete 
remission (OR)  
 1st complete remission with poor risk cytogenetics  or molecular markers;  or arising 
from preceding hematological disease  
Myelodysplastic Syndrome  
 Treatment -related  
 Monosomy 7 or complex cytogeneti cs 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
37 
  IPSS score of 1.0 or greater   
 Chronic myelomonocytic leukemia (CMML)  
Acute lymphocytic leukemia/lymphoblastic lymphoma  
 2nd or subsequent complete remission (OR)  
 Primary induction chemotherapy failure, but subsequently entered into a complete 
remission  (OR)  
 1st complete remission with poor risk cytogenetics  
Chronic Lymphocytic Leukemia / Prolymphocytic Leukemia  
 Duration of remission < 12 months after receiving chemotherapy with a nucleoside 
analog (OR)  
 High risk features ( i.e. 17p deletion) , (OR)  
 Secon d or subsequent relapse  
Hodgkin’s or Non -Hodgkin’s Lymphoma (including low -grade, mantle cell, and 
intermediate -grade/diffuse)  
 Previously treated disease that has either relapsed or failed to respond adequately to 
conventional -dose therapy or autologous tr ansplantation (AND)  
 Chemoresponsive to most recent salvage therapy  
Multiple Myeloma  
 Presence of a poor risk cytogenetic abnormality [i.e. 17p, t(4;14)]  
 Relapse post autologous transplant  
5.2     Exclusion Criteria  
Patient s meeting any of the following exclusio n criteria are not to be  enrolled in the study : 
1. Patients will not be excluded on the basis of sex, racial or ethnic background.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
38 
 2. Prior allogeneic transplant  
3. Poor cardiac function: left ventricular ejection fraction <40%  
4. Poor pulmonary function: FEV 1, FVC , or DLCO  <50% predicted  
5. Poor liver function: bilirubin >2.5 mg/dl (not due to hemolysis, Gilbert’s or primary 
malignancy) , AST/ALT > 3X ULN  
6. Poor renal function: Creatinine >2.0 mg/dl or creatinine clearance (calculated creatinine 
clearance is permitted) < 40 mL/min  
7. Ongoing or active systemic infection, active hepatitis B or C virus infection, or known 
human immunodeficiency virus (HIV) positive.  
8. Women of childbearing potential who currently are pregnant or who are not practicing 
adequate contraception  
9. Patie nts who have any debilitating medical or psychiatric illness which would preclude 
their giving informed consent or their receiving optimal treatment and follow -up.  
10. Systemic treatment, within [ADDRESS_246989] dose of MLN9708 , with strong strong 
inhibitors of CYP3A (clarithromycin, telithromycin, itraconazole, voriconazole, 
ketoconazole, nefazodone, posaconazole) or strong CYP3A inducers (rifampin, rifapentine, 
rifabutin, carbamazepi[INVESTIGATOR_050], phenytoin, phenobarbital), or use of Ginkgo biloba or St. John’s  
wort.  
11. Patient has  Grade  [ADDRESS_246990] 6  months.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
39 
 15. Known allergy to any of the study medications, their analogues, or excipi[INVESTIGATOR_207087].  
16. Known GI disease or GI procedure that could interfere with the oral absorption or tolerance 
of MLN9708 including difficulty swallowing.  
5.3    Criteria for donor selection  
1. Donors will be family members haploidentically matc hed to the recipi[INVESTIGATOR_207088] t 5/10 loci 
(HLA -A, B, C, DR, DQ) .  Half siblings are permitted as donors.  
2. Donors must be willing to donate mobilized peripheral blood progenitor cells.  
3. Donors will be selected to avoid both a positive HLA crossmatch in the host -versus -graft 
(HVG) direction and/or high titer donor specific antibodies as determined by [CONTACT_7416] -
transplant panel reactive antibody (PRA) testing.   
4. Donors will be selected preferentially to maximize NK alloreactivity in the following order 
of preference .  Priority will be given to donors with inhibitory Kir -ligand mismatches in the 
GVH direction.   In the setting of multiple possible NK alloreactive donors, preference will 
be given to donors having a group “B” Kir haplotype.   If no NK alloreactive donors are 
available, preference will be given to donors with the highest group B haplotype content28 
(appendix 2).  
6.    TREATMENT PLAN / STUDY DRUG  
6.[ADDRESS_246991] prior to 
infusion is permissible.  
Stem Cell Processing  
Minor ABO incompatible stem cell grafts will be plasma reduced and wash ed.  Major ABO 
incompatible stem cell products will not require manipulation.   
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
40 
 Preparative Regimen  
 Fludarabine  30 mg/m2 infused over 30 minutes once daily on days -6, -5, -4, -3 and -2 
(total dose, 150 mg/m2). 
 Cyclophosphamide  14.5mg/kg/d infused over 1 -2 hour s once daily on days -6 and -5 
 TBI 200 cGy to be administered in 1 fraction on day -1.   
Stem Cell Infusion  (Day of Transplant) day 0.   
Post-transplant Cyclophosphamide  
 Cyclophosphamide  50mg/kg will be given on D+[ADDRESS_246992] -transplant (within 72 hr of 
PBSC infusion) and on D+[ADDRESS_246993] -transplant. Cyclophosphamide will be given as an IV 
infusion over 2 hours . Hydration and Mesna will be given according to the institution’s 
standard of care .   
Chemotherapy Dosing :   
Fludarabine dos e will be based on actual bod y weight.  Cyclophosphamide pre -transplantation 
dose is based on the lesser of adjusted ideal body weight or actual body weight.  
Cyclophosphamide post -transplantation dosing weight is based on the lesser of actual or ideal 
body weight.   
 Ideal Body Weight  (IBW) Formulas:  
  Males IBW = 50 kg + 2.3 kg/inch over 5 feet  
  Females IBW = 45.5 + 2.3 kg/inch over [ADDRESS_246994] 2.3 kg/inch  
 Adjusted Ideal Body Weight (AIBW) Formula:  
  AIBW = IBW + [(0.25) x (ABW – IBW)]  
 Doses of Fl udarabine will be adjusted as needed according to creatinine clearance:  
  Creatinine Clearance =  (140-Age) x IBW ( x 0.85 for females)  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
41 
        72 x Serum Creatinine  
 
CHEMOTHERAPEUTIC 
AGENT  Calculated 
Creatinine 
Clearance  
46-60 ml/min  Calculated 
Creatinine 
Clearance  
31-45 ml/min  
 
Fludarabine   
80% of total 
dose  
75% of total 
dose 
 
Growth factor support:  Patients will receive G -CSF (Filgrastim) 5 mcg/kg/d SQ starting day +5 
and continuing until the ANC >1000/mm3 x 3 days or 1500/mm3 x 1 day.  
Supportive Car e: Antibiotic prophylaxis and other supportive care measures will be implemented 
according to institutional guidelines. Ciprofloxacin is not permitted while receiving MLN9708 
due to its inhibition of CYP1A2; however alternative floroquinolones are acceptab le 
(levofloxacin, moxifloxacin, gatifloxacin).  Broad -spectrum azole anti -fungal medications such 
as voriconazole, posaconazole, or itraconazole are not permitted while receiving MLN9708 due 
to its inhibition of CYP3A4.  Acceptable anti -fungal prophylaxis medications include the 
echinocandins (i.e. Micafungin) or liposomal Amphotericin (i.e. Ambisome).  
Post-transplant immunosuppression : 
 It is crucial that NO immunosuppressive agents are given until [ADDRESS_246995] -transplant Cyclop hosphamide.  This includes steroids as anti -
emetics . 
 Tacrolimus 0.03mg/kg/day infuse over 24 hours starting on day+5 (adjusted to maintain a 
trough level of 5 -15 ng/ml) and switched to oral (twice -daily divided dose) on day 21 or 
when able to tolerate p.o.   Tacrolimus will be discontinued on day +180, in the absence 
of clinically significant GVHD.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
42 
 MLN9708 (Ixazomib®) : 
 MLN9708 will be administered orally weekly x 3doses q28days, up to 12 monthly 
cycles, starting at day +[ADDRESS_246996] -transplant  (see section 6.2).    
 It will be given at a fixed dose of 4mg po with dose adjustment for hematologic or non -
hematopoietic toxicity  (see section 6.3).  
6.[ADDRESS_246997] be met and documented 
before drug administration.  Study drug will be administered  or dispensed  only to eligible 
patients under the supervision of the investigator or identified sub -investigator(s).  Patients 
should be monitored for toxicity, as necessary, and do ses of MLN9708 should be modified as 
needed to accommodate patient tolerance to treatment; this may include symptomatic treatment, 
dose interruptions, and adjustments of MLN9708 dose (see Section 6.3). 
Capsules of MLN9708 will also be referred to as study drug.  Study drug will be supplied by 
[CONTACT_20552] 2.3, 3.0 and 4.0  mg MLN9708.  MLN9708 will be administered at a 
fixed dose of 4mg orally weekly x 3doses , q28days, up to 12 monthly cycles, starting at day +[ADDRESS_246998]-transplant , with dose adjustm ent for hematologic or non -hematopoietic toxicity (see Section 
6.3).  
Patients should be instructed to swallow MLN9708 capsules whole, with water, and not to break, 
chew, or open the capsules.  Study drug should be taken on an empty stomach (no food or dri nk) 
at least 1 hour before or 2  hours after a meal.  Each capsule should be swallowed separately with 
a sip of water.  A total of approximately 8 ounces (240 mL) of water should be taken with the 
capsules.   
Missed doses can be taken as soon as the patient  remembers if the next scheduled dose is 
[ADDRESS_246999].  A double dose should not be taken to make up for a missed dose In case 
of vomiting repeat doses should be given as follows:  
1. If vomiting occurs within [ADDRESS_247000] 72 hours before the next scheduled dose.   
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
43 
 2. If  vomiti ng occurs within 30 minutes of taking a dose and no capsule  is found then 50% 
of the dose should be repeated.  Patients assigned dose level -2 (2.3mg) will receive 
1.5mg as the repeat dose.  Repeat dosing should occur as soon as nausea has resolved. 
Unexp ected delays in repeat dosing are acceptable as long as dosing is complete at least 
72 hours before the next scheduled dose.   
3. If vomiting occurs 30 -60 minutes after a dose then 50% of the dose should be repeated, 
regardless of vomitus contents.  Patients assigned dose level -2 (2.3mg) will receive 
1.5mg as the repeat dose. Repeat dosing should occur as soon as nausea has resolved. 
Unexpected delays in repeat dosing are acceptable as long as dosing is complete at least 
72 hours before the next scheduled dos e.   
4. If vomiting occurs more than 60 minutes after a dose the patient should not repeat the 
dose but should resume dosing at the time of the next scheduled dose.   
MLN9708 Destruction  
Investigational MLN9708 (expi[INVESTIGATOR_20538]) should be destroyed on  site according to the 
institution’s standard operating procedure.  Removal and destruction of all drug will be 
documented on drug accountability logs.  
6.3    Dose -Modification Guidelines   
6.3.1  Recommended MLN9708 Criteria for Beginning or Delaying a Subsequent 
Treatment Cycle &  Dose Modifications for Treatment Associated Toxicity  
Treatment with MLN9708 will use a cycle length of 28 days. Cycle #1 will begin regardless of 
ANC or platelet count and continue for the full cycle.  During cycle #1, MLN9708 will only be  
held or dose modified for grade 3 -4 non -hematologic toxicity, judged to be related to study drug.  
If MLN9708 is held during cycle #1, mycophenolate 15mg/kg three times daily (3 grams 
maximum daily dose) may be given at MD discretion.  For a ny new cycle o f treatment to begin, 
the patient must meet the following criteria:  
 ANC must be ≥ 1,000/mm3 (can be supported with growth factor support).  
 Platelet count must be ≥ 50,000/mm3. 
 All other nonhematologic toxicity (except for alopecia) must have resolved to ≤ Grade 1 
or to the patient’s baseline condition  
If the patient fails to meet the above -cited criteria for initiation of the next cycle of treatment, 
dosing should be delayed  until resolution of toxicity per tables 6 -2 and 6 -3.. The maximum delay 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
44 
 before trea tment should be discontinued will be 4 weeks or at the discretion of the Principal 
Investigator.  
For dosing recommendations upon recovery, refer to Table 6 -2 and Table 6 -3. 
Table 6 -1 MLN908 Dose Adjustments  
 
Dose Level  Dose (mg)  
Starting Dose  4.0 mg  
-1 3.0 mg  
-2 2.3 mg  
-3 Discontinue  
Dosage adjustments for hematologic toxicity are outlined i n Table 6 -2. 
Table 6-2    MLN9708 Dose Adjustments for Hematologic Toxicities  
  
  
    
  
    
  
   
  
Criteria  Action  
 If ANC <1.0 x 109/L or platelet count 
<50x109/L prior to the start of a new 
cycle (other than cycle 1)  
 OR 
 If platelet count falls to ≤30 x 109/L or 
ANC≤0.50 x 109/L after initiating a cycle 
but before day 15   Hold MLN9708 until resolution as per 
section 6.2  
 Upon recovery, MLN9708 may be 
reinitiated with 1 dose level reduction  
 If platelet count falls to ≤30 x 109/L or  Reduce MLN9708 by 1 dose level at the 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
45 
 ANC≤0.50 x 109/L after day 15  but 
recovers in time for the start of the next 
cycle  start of the next cycle  
 
Treatment modifications due to MLN9708 -related  AEs are outlined in Table 6 -3. 
Table 6-3    MLN9708 Treatment Modification (Delays, Reductions, and 
Discontinuations) Due to Adverse Events (Non -Hematologic Toxicities)  
Adverse Event (Severity)  Action on Study Drug  Further Considerations  
Peripheral Neuropathy : 
Grade 1 peripheral neuropathy   
 No action   
Grade 1 signs and symptoms:  
asymptomatic; without pain or loss 
of function; clinical or diagnostic 
observations onl y60 
 
 
New or worsening Grade 1 
peripheral neuropathy with pain or 
Grade 2  (other than cycle 1)   Hold study drug until 
resolution to Grade ≤ 1 or 
baseline  Grade 2 signs and symptoms:  
Moderate symptoms; limiting 
instrumental activities of daily 
living (ADL )60 
 
 
New or worsening Grade 2 
peripheral neuropathy with pain 
(other than cycle 1) or Grade 3  
(any cycle)   Hold study drug until 
resolution to Grade ≤ 1 or 
baseline  
 Reduce study drug to next 
lower dose upon recovery  
 Grade 3 signs and symptoms:  
severe symptoms; limiting self -
care ADL; assistive device 
indicate d60 
New or worsening Grade 4 
peripheral  neuropathy   Discontinue study drug   
 
 
Grade 2 Rash   Symptomatic 
recommendations as per 
section 6.[ADDRESS_247001] 
clinician may discuss 
considerations for dose 
modifications and symptom 
management.  
 
Grade 3 nonhematologic toxicity 
judged to be related to study drug   
 Hold study drug until 
resolution to Grade < 1 or 
baseline   
Symptomatic recommendations 
noted in Section  6.7 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
46 
 Table 6-3    MLN9708 Treatment Modification (Delays, Reductions, and 
Discontinuations) Due to Adverse Events (Non -Hematologic Toxicities)  
Adverse Event (Severity)  Action on Study Drug  Further Considerations  
If not recovered to 
< Grade 1 or baseline 
within 4 weeks  
  Reduce study drug  to next 
lower dose upon return to 
< Grade 1 o r baseline   
Subsequent recurrence 
Grade 3 that does not 
recover to < Grade 1 or 
baseline within 4 weeks   Hold study drug until 
resolution to Grade < 1 or 
baseline  
 Reduce study drug to next 
lower dose  Monitor closely, take appropriate 
medical precautions, and provide 
appropriate symptomatic care  
 
Grade 4 nonhematologic toxicities 
judged to be related to study drug   
 Consider permanently 
discontinuing study drug   
Exceptions are cases in which the 
investigator determines the patient 
is obtaining a clinical be nefit  
 
Dose Re -Escalation:  
 If MLN9708 is reduced for any nonhematologic toxicity  judged related to study drug , the 
dose may not be re -escalated.    
 If MLN9708 is reduced for hematologic toxicity, the dose may be re -escalated at the 
discretion of the princ ipal investigator.  
6.4    Excluded Concomitant Medications and Procedures  
The following medications and procedures are prohibited during the study:  
Systemic treatment with any of the following metabolizing enzyme inhibitors is not permitted 
during this study.   A DDI with a strong inhibitor would increase MLN2238 exposure.  
 Strong inhibitors of CYP1A2:  fluvoxamine, enoxacin, ciprofloxacin  
 Strong inhibitors of CYP3A:  clarithromycin, telithromycin, itraconazole, voriconazole, 
ketoconazole, nefazodone, and posaco nazole  
Systemic treatment with any of the following metabolizing enzyme inducers should be avoided 
unless there is no appropriate alternative medication for the patient to use.  A DDI with a strong 
inducer would decrease MLN2238 exposure.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
47 
  Strong CYP3A indu cers:  rifampin, rifapentine, rifabutin, carbamazepi[INVESTIGATOR_050], phenytoin, and 
phenobarbital  
The use of NSAIDS should be avoided  
The dietary supplements St John’s wort and Ginkgo biloba are not permitted.  
The following procedures are prohibited during the study:  
 Any antineoplastic treatment with activity against hematologic malignancies  except for 
drugs in this treatment regimen   
 Radiation therapy (the requirement for local radiation therapy generally indicates disease 
progression).     
6.5 Permitted Concomitant Medica tions and Procedures  
 G-CSF (filgrastim) will be given post transplant as described in section 6.1.  
Erythropoietin , if used, should follow published guidelines and/or institutional practice.  
 Supportive measures consistent with optimal patient care ma y be given throughout the 
study.   
6.6    Precautions and Restrictions  
Fluid deficits should be corrected before and throughout treatment.  
Nonsteroidal anti -inflammatory drugs (NSAIDs) induced prevalence of nephrotoxicity is 
relatively low; however, given the wide  use of these agents many persons are at risk, including 
for example, patients with cardio -renal disease, dehydration, and the aging kidney. NSAIDs 
should be avoided with impaired renal function given reported NSAID -induced renal failure in 
patients with d ecreased renal function.   
Pregnancy  
It is not known what effects  MLN9708  has on human pregnancy or development of the embryo 
or fetus.  Therefore, female patients participating in this study should avoid becoming pregnant, 
and male patients should avoid im pregnating a female partner.  No n-sterilized female patients of 
reproductive age group and male patients should use effective methods of contraception through 
defined periods during and after study treatment as specified below.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
[ADDRESS_247002] meet 1 of the following  criteria :  
 Postmenopausal for at least 1 year before the screening visit, OR 
 Surgically sterile, OR 
 If they are of childbearing potential, agree to practice [ADDRESS_247003] dose of study drug, AND  
 Agree to practice true abstinence when this is in line with the preferred and usual lifestyle 
of the subject.  (Periodic abstinence [e.g., calendar, ovulation, symptothermal, p ost-
ovulation methods] and withdrawal are not acceptable methods of contraception.)  
Male patients, even if surgically sterilized (i.e., status post -vasectomy), must agree to 1 of the 
following:  
 Agree to practice effective barrier contraception during the e ntire study treatment period 
and through [ADDRESS_247004] dose of study drug, OR  
 Agree to practice true abstinence when this is in line with the preferred and usual lifestyle 
of the subject.  (Periodic abstinence (e.g., calendar, ovulation, symptothe rmal, post -
ovulation methods] and withdrawal are not acceptable methods of contraception.)  
6.[ADDRESS_247005] disease (GVHD)  
In the setting of grade II-IV acute GVHD or moderate -severe cGVHD, MLN9708 should be 
discontinued.  Upon resolution of GVHD, consideration could be given to restarting 
investigational drug at the discretion of the principal investigator.  
Prophylaxis Against Risk of Infection  
If lymphopenia is noted, patients may be at an increased risk of infection.  In particular, 
lymphopenia can be associated with reactivation of herpes zoster and herpes simplex viruses.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
49 
 Antiviral therapy such as acyclovir or valacyclovir may be initiated as c linically indicated.  Other 
antivirals are also acceptable.  
Nausea and/or Vomiting  
Standard anti -emetics, including 5 -HT 3 antagonists, are recommended for emesis occurring upon 
treatment initiation; prophylactic anti -emetics may also be considered.  .  Flu id deficits should be 
corrected before initiation of study drug  and during treatment . 
Diarrhea  
Diarrhea should be managed according to clinical practice, including the administration of anti -
diarrheals once infectious causes are excluded.  Fluid intake sho uld be maintained to avoid 
dehydration.  Fluid deficits should be corrected before initiation of treatment  and during 
treatment . Prophylactic anti -diarrheals are not generally recommended.  
Erythematous Rash With or Without Pruritus  
As with VELCADE, rash wi th or without pruritus has been reported with MLN9708, primarily at 
the higher doses tested. The rash may range from some erythematous areas, macular and/or small 
papular bumps that may or may not be pruritic over a few areas of the body or more generalize d, 
has been transient and has resolved either spontaneously or with standard symptomatic measures 
such as oral or topi[INVESTIGATOR_207089]/or antihistamines . Prophylactic measures should also be 
considered if a patient develops a rash (e.g., using a thick, alc ohol-free emollient cream on dry 
areas of the body).  A rare risk is Steven s-Johnson Syndrome, a severe, life -threatening or deadly 
rash with skin peeling and mouth sores, which should be managed symptomatically according to 
standard medical practice.   
Thrombocytopenia  
Thrombocytopenia has been reported to date primarily at the higher doses tested .  Blood counts 
should be monitored regularly as outlined in the protocol with additional testing obtained 
according to standard clinical practice.  Thrombocytopen ia may be severe but has been 
manageable with platelet transfusions according to standard clinical practice. Thrombocytopenia 
nadirs commonly recover without intervention by [CONTACT_207119]. 
MLN9708 administration should be modifi ed as noted as per dose modification 
recommendations in Table 6-2 when thrombocytopenia occurs.  Therapy can be reinitiated at a 
reduced level upon recovery of platelet counts.  A rare risk is thrombotic thrombocytopenic 
purpura (TTP), a rare blood disorder  where blood clots form in small blood vessels throughout 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
[ADDRESS_247006] been reported with MLN9708. 
Blood pressure should be closely monitored while the patient is on study treatment and fluid 
deficit should be corrected as needed, especially in th e setting of concomitant symptoms such as 
nausea, vomiting, diarrhea, or anorexia. Patients taking medications and/or diuretics to manage 
their blood pressure (for either hypo - or hypertension) should be managed according to standard 
clinical practice, inc luding considerations for dose adjustments of their concomitant medications 
during the course of the trial.   
Posterior Reversible Encephalopathy Syndrome  
One case of posterior reversible encephalopathy syndrome (PRES) has been reported with 
MLN9708.  Whil e this case ultimately resolved, PRES has also been reported rarely with another 
proteasome inhibitor, VELCADE.  PRES is characterized by [CONTACT_12704], seizures and visual loss, 
as well as abrupt increase in blood pressure.  Prompt diagnosis and initiation of antihypertensive 
and anticonvulsant therapy are important to prevent irreversible end -organ damage.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
51 
 6.8  Preparation, Reconstitution, and Dispens ing 
MLN9708 is an anticancer drug and as with other potentially toxic compounds caution should be 
exercised when h andling MLN9708 capsules.  
6.9  Packaging and Labeling  
The study drug MLN9708 capsules will be provided by [CONTACT_20555].  The study drug will be 
labeled and handled as open -label material, and packaging labels will fulfill all requirements 
specified by [CONTACT_207120].   
MLN9708 capsules should  be stored unopened at 2°C to 8°C (36°F -46°F).  The capsules are 
individually packaged in cold form foil -foil blisters in a child -resistant package .  The 0.2-, 0.5-, 
and 2.0 mg capsules are in 1  4 blister strips tha t are individually perforated.  The strips (1  4) 
are placed in cartons containing 6 strips (24 total capsules) of the same strength.  The 2.[ADDRESS_247007] wallet.  
6.10  Storage , Handling, and Accountability  
Upon receipt at the investigative site, MLN9708 should remain in the blister and carton provided 
until use or until drug is dispensed. The container should be stored at the investigative site 
refrigerated (36°F to 46°F, 2°C t o 8°C). Ensure that the drug is used before the retest expi[INVESTIGATOR_20540]. Expi[INVESTIGATOR_20541].  
In countries where local regulations permit, MLN970 [ADDRESS_247008] daily d ose configurations. Comprehensive instructions should be provided to the 
patient in order to ensure compliance with dosing procedures. Patients who are receiving take -
home medication should be given only 1 cycle of medication at a time. Patients should be 
instructed to store the medication refrigerated (36°F to 46°F, 2°C to 8°C) for the duration of each 
cycle. Patients should be instructed to return their empty blister packs to the investigative site, 
rather than discarding them. Reconciliation will occur a ccordingly when the patient returns for 
their next cycle of take -home medication. Any extreme in temperature should be reported as an 
excursion and should be dealt with on a case -by-case basis.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
[ADDRESS_247009] with the powder (e.g., from a broken capsule), skin should be washed 
immediately with soap and copi[INVESTIGATOR_12666]  [ADDRESS_247010] 
capsules.  
6.11      Study Compliance  
Study drug will be administered or dispensed only to eligible patients under the supervision of 
the investigator or identified sub -investigator(s).  The appropriate st udy personnel will maintain 
records of study drug receipt and dispensing.  
6.12   Termination of Treatment and/or Study Participation  
Patients will be informed that they have the right to withdraw from the study at any time for any 
reason, without prejudice to their medical care.  The investigator also has the right to withdraw 
patients from the study for any of the following reasons:  
 Adverse event  
 Protocol violation  
 Lost to follow -up 
 Progressive disease  
 Study terminated  
 Other  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
53 
 At the time of withdraw al, all stu dy procedures outlined for the End of Study visit should be 
completed. The primary reason for patient’s withdraw al from the study should be recorded in the 
source documents and CRF.  
7.    STATISTICAL AND QUAN TITATIVE ANALYSES  
7.1    Statistical Methods  
7.1.1      Determination of Sample Size  
The primary endpoint of this trial will be the risk of relapse and/or progression at one -year post -
transplant.  Experience from the literature suggests that following a nonmyeloablative  
haploidentical transplant using post -transpl ant cyclophosphamide (haplo -pCy), the risk of relapse 
is approximately 50% at one year post -transplant61.  It is hoped that under this protocol, this rate 
will be at most 25%. Thus we statistically formalize this study by [CONTACT_207102] 
p, the PFS rate is 0.25 or less versus the alternative hypothesis that p is greater than 0.5. A 
sample size of 25 patients gives 90% power with an alpha=0.05, using the formula for a one 
sample binomial (two -sided) test of a proportion.  Accrual will contin ue unless a stoppi[INVESTIGATOR_207090].  We expect that patients will be accrued over 2 years.  
7.1.2     Stoppi[INVESTIGATOR_207091] : As outlined in Section 1 (Background), the overall non -relapse mortality (NRM) on the 
nonmyeloablative haploidentical HSCT trial utiliz ing post -transplantation Cy, MMF and 
tacrolimus is approximately 19% at one year. Consequently a NRM incidence that is 
convincingly greater th an 20% would raise concerns for excessive toxicity. This trigger would be 
met if NRM occurs in [ADDRESS_247011] 15 
patients. If the stoppi[INVESTIGATOR_196140], accrual to the trial will be temporarily halted until a 
decision regarding either modification or termination of the trial could be made.  
Severe acute GVHD  (aGVHD) : As outlined in Section 1 (Background), the expected incidence 
of severe aGVHD (Grades III -IV)) on the nonmyeloablative haploidentical HSCT utilizing post -
transplantation Cy, MMF and tacrolimus is approximately 10%. The working hypothesis of t his 
trial is that the overall toxicity of fully ablative haploidentical HSCT is not significantly greater 
than haploidentical HSCT after nonmyeloablative conditioning utilizing post -transplantation Cy. 
Consequently, an incidence of severe aGVHD convincingl y greater than 15% would raise 
concerns for excessive toxicity. This trigger would be met if severe aGVHD occurs in [ADDRESS_247012] 15 patients. If the stoppi[INVESTIGATOR_207092] & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
54 
 met, accrual to the trial  will be temporarily halted, until a decision regarding either modification 
or termination of the trial could be made.  
Engraftment Failure:  As outlined in Section 1 (Background), the incidence of engraftment 
failure on the nonmyeloablative haploidentical  HSCT trial utilizing post -transplan tation Cy, 
MMF and tacrolimus i s approximately 18%. Consequently a graft failure incidence that is 
convincingly greater th an 20% would raise concerns for excessive toxicity. This trigger would be 
met if graft failure  occurs in [ADDRESS_247013] 
15 patients. If the stoppi[INVESTIGATOR_196140], accrual to the trial will be temporarily halted until a 
decision regarding either modification or termination of the trial co uld be made.  
Excessive Toxicity (defined as toxicities CTCAE v.3 grade 4 or higher considered probably 
or definitely related to the study drug) : There is significant potential and/or expected toxicity 
that occurs in the first 4 weeks following allogeneic transplant, including severe cytopenias 
(neutropenia, anemia, thrombocytopenia), renal insufficiency, hypokalemia, hypomagnesaemia, 
hepatic sinusoidal obstruction syndrome, nausea, vomiting, diarrhea, mucositis/enteritis, fever, 
life-threatening infections , thrombotic microangiopathy, graft rejection, and graft -versus -host 
disease.  However, excessive toxicity that is convincingly greater than 15% would raise 
concerns. This trigger would be met if grade ≥[ADDRESS_247014] who h as signed 
informed consent to participate in a study but before administration of any study medication; it 
does not necessarily have to have a causal relationship with study participation . 
8.1.2        Adverse Event Definition  
Adverse event (AE) means any untowa rd medical occurrence in a patient or subject administered 
a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
55 
 (including  an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal (investigational) product whether or not it is related to the medicinal product.  
This includes any newly occurring event, or a previous condition that has increased in severity or 
frequency since the administration of study drug.  
An abnormal laboratory value will not be assessed as an AE unless that value leads to 
discontinuation or delay in treatment, dose modification, therapeutic intervention, or is 
considered by [CONTACT_2418] a clinically significant change from baseline.    
8.1.3     Serious Adverse Event Definition  
Serious AE (SAE) means any untoward medical occurrence that at any dose:  
 Results in death.  
 Is life-threatening (refers to an AE in whi ch the patient was at risk of death at the time of 
the event.  It does not refer to an event which hypothetically might have caused death if it 
were more severe).  
 Requires inpatient  hospi[INVESTIGATOR_1324]  (see 
clarif ication  in the paragraph below on planned hospi[INVESTIGATOR_602]).  
 Results in persistent or significant disability or incapacity . (Disability is defined as a 
substantial disruption of a person’s ability to conduct normal life functions).  
 Is a congenital anomaly/ birth defect . 
 Is a medically important event .  This refers to an AE that may not result in death, be 
immediately life threatening, or require hospi[INVESTIGATOR_059], but may be considered serious 
when, based on appropriate medical judgment, may jeopardize the pat ient, require 
medical or surgical intervention to prevent [ADDRESS_247015] of an infectious agent.   Examples of such 
medical events include allergic bronchospasm requiring intensive  treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse; any 
organism, virus, or infectious particle (e.g., prion protein transmitting Transmissible 
Spongiform Encephalopathy), pathogenic or nonpathogenic, is considered an infectious 
agent.   
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
56 
 Clarification should be made between a serious AE (SAE) and an AE that is considered severe in 
intensity (Grade 3 or 4), because the terms serious a nd severe are NOT synonymous.  The 
general term severe  is often used to describe the intensity (severity) of a specific event; the event 
itself, however, may be of relatively minor medical significance (such as a Grade 3 headache).  
This is NOT the same as  serious , which is based on patient/event outcome or action criteria 
described above, and  is usually associated with events that pose a threat to a patient’s life or 
ability to function.  A severe AE (Grade 3 or 4) does not necessarily need to be considere d 
serious.  For example, a white blood cell count of 1000/mm3 to less than 2000 is considered 
Grade 3 (severe) but may not be considered serious.  Seriousness (not intensity) serves as a guide 
for defining regulatory reporting obligations.  
8.1.[ADDRESS_247016] (AESIs) are a subset of AEs that are to be reported to 
Millennium on a quarterly basis by [CONTACT_456] -investigator. Millennium will provide the current 
list of AESIs and updates to the lis t will be distributed to the sponsor -investigator as appropriate  
8.2    Procedures for Reporting Serious Adverse  Events  
AEs may be spontaneously reported by [CONTACT_5363]/or in response to an open question from 
study personnel or revealed by [CONTACT_4171], ph ysical examination, or other diagnostic 
procedures .  Any clinically relevant deterioration in laboratory assessments or other clinical 
finding is considered an AE.  When possible, signs and symptoms indicating a common 
underlying pathology should be noted as one comprehensive event.   For serious AEs, the 
investigator must determine both the intensity of the event and the relationship of the event to 
study drug administration. For serious pretreatment events, the investigator must determine both 
the intensit y of the event and the relationship of the event to study procedures.  
AEs which are serious must be reported to Millennium Pharmacovigilance (or designee) from 
the date the participant receives the first dose of study drug  through [ADDRESS_247017] of MLN9708. Any SAE that occurs at any time during treatment with MLN9708 
or for 60 days after the  completion of  MLN9708  treatment that the sponsor -investigator and/or 
sub-investigator considers to be related to any study drug must be  reported to Millennium 
Pharmacovigilance (or designee).   In addition, new primary malignancies that occur during the 
follow -up periods must be reported, regardless  of causality to study regime n, for a minimum of  
three  years  after the last dose of the inve stigational product, starting from the first dose of study 
drug. All new cases of primary malignancy must be reported to Millennium Pharmacovigilance 
(or designee).     
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
57 
 Planned hospi[INVESTIGATOR_207093] d before 
the patient was enrolled in the trial are not to be considered AEs unless the condition deteriorated 
in an unexpected manner during the trial (e.g., surgery was performed earlier or later than 
planned).  All SAEs should be monitored until they are  resolved or are clearly determined to be 
due to a patient’s stable or chronic condition or intercurrent illness(es).  
Since this is an investigator -initiated study, the principal investigator , Scott R. Solomon, MD , 
also referred to as the sponsor -investiga tor, is responsible for reporting serious adverse events 
(SAEs) to any regula tory agency and to the sponsor -investigator’s EC or IRB.    
Regardless of expectedness or causality, all SAEs (including serious pretreatment events) must 
also be reported to Mill ennium Pharmacovigilance:  
Fatal and Life Threatening SAEs within 24 hours but no later than 4 calendar days of the 
sponsor -investigator’s observation or awareness of the event  
 
All other serious (non -fatal/non life threatening) events within 4 calendar day s of the sponsor -
investigator’s observation or awareness of the event  
 
The protocol may include language to specify expected adverse events which will not be 
considered serious and will not require expedited reporting.  
The sponsor -investigator must fax the  SAE Form per the timelines above.   A sample of an SAE 
Form will be provided.    
The SAE report must include at minimum:  
 Event term(s)  
 Serious criteria  
 Intensity of the event(s):  Sponsor -investigator’s or sub -investigator’s 
determination.   Intensity for eac h SAE, including any lab abnormalities, will be 
determined by [CONTACT_128751], as a 
guideline, whenever possible.   The criteria are available online at 
http://ct ep.cancer.gov/reporting/ctc.html . 
 Causality of the event(s): Sponsor -investigator’s or sub -investigator’s 
determination of the relationship of the event(s) to study drug administration.  
Follow -up information on the SAE may be requested by [CONTACT_20555].    
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
58 
  Intensity for each SAE, including any lab abnormalities, will be determined by [CONTACT_207121], as a guideline, whenever possible.   The criteria are 
available online at http://ctep.cancer.gov/reporting/ctc.html . 
In the event that this is a multisite study, the sponsor -investigator is responsible to ensure that the 
SAE reports are sent to Millennium Pharmacovigilance (or designee) from all sites participating 
in the study.   Sub-investigators must report all SAEs to the sponsor -investigator so that the 
sponsor -investigator can meet his/her foregoing reporting obligations to the required regulatory 
agencies and to Millennium Pharmacovigilance, unless otherwise agreed between the sponsor -
investigator and sub -investigator(s).    
Relationship to all study drugs for each SAE will be determined by [CONTACT_9940] -
investigator by [CONTACT_91854]: Is there a reasonable possibility that the AE 
is associated with the study drug(s)?  
Sponsor -investigator must also provide Millennium Pharmacovigilance with a copy of all 
communications with applicable regulatory authorities related to the study or study drug(s), 
including, but not limited to, telephone co nversation logs within [ADDRESS_247018] Information  
Cognizant Contacts Fax Number: 1 -[PHONE_4452]  
Email: takedaoncocases@c ognizant.com  
Suggested Reporting Form:   
• SAE Report Form (a sample is provided in Appendix 13.3) 
• US FDA MedWatch 3500A:  
http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm  
8.3    Procedures for Reporting AESIs  
AEs may be spontaneousl y reported by [CONTACT_5363]/or in response to an open question from 
study personnel or revealed by [CONTACT_4171], physical examination, or other diagnostic 
procedures .  Any clinically relevant deterioration in laboratory assessments or other clinical 
findi ng is considered an AE.  When possible, signs and symptoms indicating a common 
underlying pathology should be noted as one comprehensive event.   For nonserious AEs  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
59 
 (including AESIs) , the investigator must determine both the intensity of the event and the 
relationship of the event to study drug  administration.  
AESIs must be reported to Millennium on a quarterly basis.  
8.[ADDRESS_247019] immediately fax a completed Pregnancy Form to the Millennium 
Department of Pharmacovigilance or designee  (see Section 8.2).  The pregnancy must be 
followed for the final pregnancy outcome.  
If a female partner of a male patient becomes pregnant during the male patient’s participation in 
this study, the sponsor -investigator  must also immediately fax a completed Pre gnancy Form to 
the Millennium Department of Pharmacovigilance or designee  (see Section 8.2).  Every effort 
should be made to follow the pregnancy for the final pregnancy outcome.  
Suggested Pregnancy Reporting Form:  
 Pregnancy Report Form (a sample is provid ed in Appendix 12. )   
9.    ADMINISTRATIVE REQUI REMENTS  
9.1    Good Clinical Practice  
The study will be conducted in accordance with the International Conference on Harmoni sation 
(ICH) for Good Clinical Practice (GCP) and the appropriate regulatory requirement( s).  The 
investigator will be thoroughly familiar with the appropriate use of the study drug as described in 
the protocol and Investigator’s Brochure.  Essential clinical documents will be maintained to 
demonstrate the validity of the study and the integri ty of the data collected.  Master files should 
be established at the beginning of the study, maintained for the duration of the study and retained 
according to the appropriate regulations.   
9.2    Ethical Considerations  
The study will be conducted in accorda nce with applicable regulatory requirement(s) and will 
adhere to GCP standards .  The IRB/IEC will review all appropriate study documentation in order 
to safeguard the rights, safety and well -being of the patients.  The study will be conducted only 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
60 
 at sites  where I RB/IEC approval has been obtained.  The protocol, Investigator’s Brochure, 
informed consent form, advertisements (if applicable), written information given to the patients 
(including diary cards), safety updates, annual progress reports, and any re visions to these 
documents will be provided to the IRB/IEC by [CONTACT_093].  Millennium requests that 
informed consent documents be reviewed by [CONTACT_207122]/IEC 
submission.    
9.3    Patient  Information and Informed Consent  
After the  study has been fully explained, written informed consent will be obtained from either 
the patient or his/her guardian or legal representative before study participation.  The method of 
obtaining and documenting the informed consent and the contents of the  consent must comply 
with the ICH -GCP and all applicable regulatory requirements . 
9.4    Patient  Confidentiality  
In order to maintain patient privacy, all data capture records, drug accountability records, study 
reports and communications will identify the pa tient by [CONTACT_44144].  
If requested, the  investigator will grant monitor(s) and auditor(s) from Millennium or its 
designees and  regulatory authority(ies) access to the patient’s original medical records for 
verification of data  gathered on the data capture records and to audit the data collection process.  
The patient’s confidentiality will be maintained and will not be made publicly available to the 
extent permitted by [CONTACT_4913].  
9.[ADDRESS_247020] the study in compliance with the protocol given approval/favorable 
opi[INVESTIGATOR_1686]/IEC and the appropriate regulatory authority(ies).  Changes to the protocol 
will require approval from Millennium and written IRB/IEC approval/favorable opi[INVESTIGATOR_146949], except when the modification is needed to eliminate an immediate hazard(s) to 
patients.  The IRB/IEC may provide, if applicable regulatory authority(ies) permit, expedited 
review and approval/favorable op inion for minor change(s) in ongoing studies that have the 
approval /favorable opi[INVESTIGATOR_1100]/IEC.  The investigator will submit all protocol 
modifications to Millennium and the regulatory authority(ies) in accordance with the governing 
regulations.  
Any departures from the protocol must be fully documented in the source documents.   
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
61 
 9.6    On-site Audits  
Regulatory authorities , the IEC/IRB and/or Millennium may request access to all source 
documents, data capture records, and other study documentation for  on-site audit or inspection.  
Direct access to these documents must be guaranteed by [CONTACT_093], who must provide 
support at all times for these activities.  
9.7    Investigator and Site Responsibility for Drug Accountability  
Accountability for the study drug at all study site s is the responsibility of the principal 
investigator.  The investigator will ensure that the drug is used only in accordance with this 
protocol.  Drug accountability records indicating the drug’s delivery date to the site, inventor y at 
the site, use by [CONTACT_4143], and amount returned to Millennium or a designee or disposal of the 
drug (if applicable and  if approved by [CONTACT_20555]) will be ma intained by [CONTACT_977].  
Accountability records will include dates, quantities, lot n umbers, expi[INVESTIGATOR_1659] (if 
applicable), and patient numbers.   
9.[ADDRESS_247021] MedComm Solutions 
(see below) and report the event.  Whenever possible, the associated product should be 
maintained in accordance with the label instr uctions pending further guidance from a Millennium 
Quality representative.  
 
 
For Product Complaints,  
call MedComm Solutions at  
[PHONE_3715] (877 MPI [INVESTIGATOR_53308])   
(US and International)  
 
Product complaints in and of themselves are not AEs.  If a product complaint  results in an SAE, 
an SAE form should be completed and sent to [COMPANY_003]  (refer to S ection  8.2). 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
62 
 9.9    Closure of the Study  
This study may be prematurely terminated, if in the opi[INVESTIGATOR_149611], 
there is sufficient reasonable cause.  Writt en notification documenting the reason for study 
termination will be provided to the investigator or Millennium by [CONTACT_51272].   
Circumstances that may warrant termination include, but are not limited to:  
 Determination of unexpected, significant , or unacceptable risk to patients  
 Failure to enter patients at an acceptable rate  
 Insufficient adherence to protocol requirements  
 Insufficient , incomplete and/or unevaluable data  
 Determination of efficacy based on interim analysis  
 Plans to modify, suspend  or discontinue the development of the drug  
9.[ADDRESS_247022] Retention  
The investigator will maintain all study records according to the ICH -GCP and applicable 
regulatory requirement(s).   
10.    USE OF INFORMATION  
All information regarding  MLN9708  supplied by [CONTACT_207123].  The investigator agrees to use this information to accomplish the 
study and will not use it for other purposes without consent from Millennium.  It is understood 
that there is an oblig ation to provide Millennium with complete data obtained during the study.  
The information obtained from the clinical study will be used toward the development of  
MLN9708  and may be disclosed to regulatory authority(ies), other investigators, corporate 
partners, or consultants as required.  
Upon completion of the clinical study and evaluation of results by [CONTACT_20555], the hospi[INVESTIGATOR_171774]/or investigator may publish or disclose the clinical trial results pursuant to the 
terms contained in the appl icable Clinical Trial Agreement.      
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
63 
 11.  DISEASE EVALUATION62, 63 
Relapse of Malignancy  – Testing for recurrent malignancy in the blood, marrow or other sites 
will be used to assess relapse after transplantation.  For the purpose of this study, relapse is 
defined by [CONTACT_207124] -
transplant features, or radiologic evidence (including the recurrence of fluoro -deoxyglucose 
[FDG] -avid lesions on PET scan) of progressive lymphoma.  When in doubt , the diagnosis of 
recurrent or progressive lymphoma should be documented by [CONTACT_102135].   
Minimal Residual Disease – Minimal residual disease is defined by [CONTACT_207125], or fluorescent in situ hybridization (FI SH), or Southern blot, 
or Western blot, or polymerase chain reaction (PCR), or other techniques, in absence of 
morphological or cytogenetic evidence of disease in blood or marrow.  Since the frequency of 
testing for minimal residual disease is highly varia ble among centers, and the sensitivity is highly 
variable among laboratory techniques, evidence of minimal residual disease alone will not be 
sufficient to meet the definition of relapse in the context of this trial.  However, minimal residual 
disease that  progresses (see above) will be considered as relapse and the date of relapse will be 
the date of detection of minimal residual disease that prompted an intervention by [CONTACT_30780].  Data on tapering immunosuppression, administering chemotherapy  or biological 
agents to in response to detection of minimal residual disease will be captured in the case report 
forms.  
Acute Leukemia  – Relapse will be diagnosed when there is:  
1. The reappearance of leukemia blast cells in the peripheral blood; or,  
2. > 5% bl asts in the marrow, not attributable to another cause (e.g., bone marrow 
regeneration); or  
3. The development of extramedullary leukemia or leukemic cells in the cerebral spi[INVESTIGATOR_207094]  
4. The reappearance of cytogenetic abnormalities present prior to transplan tation  
 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
64 
 Lymphoma  – Relapse will be diagnosed when there is:  
1. Appearance of any new lesion more than 1.[ADDRESS_247023] a 50% increase from nadir in the sum of the product diameters (SPD) of any 
previously involved nodes, or in a single involved node, or the size of other lesions (e.g., 
splenic or hepat ic nodules).  To be considered progressive disease, a lymph node with a 
diameter of the short axis of less than 1.[ADDRESS_247024] increase by  50% and to a size of 1.5 
x 1.5 cm or more than 1.5 cm in the long axis.  
Lesions should be PET positive if observed in  a typi[INVESTIGATOR_20359] -avid lymphoma or the 
lesion was PET positive before therapy unless the lesion is too small to be detected with 
current PET systems (<.1.[ADDRESS_247025]).  
 Institution of any therapy to treat persistent, progressive or relapsed di sease, including 
withdrawal of immunosuppressive therapy or DLI, will be considered evidence of 
relapse/progression regardless of whether the criteria described above are met.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
65 
 TABLE 11.1 RESPONSE CRITERIA FOR LYMPHOMA64 
 
 
Respon se Criteria for Acute Leukemia  
Remission is defined as < 5% blasts with no morphological characteristics of acute leukemia 
(e.g., Auer Rods) in a bone marrow with > 20% cellularity, peripheral blood counts showing 
ANC >1000/ l, including patients in CRp.  
Response Criteria for Lymphoma  
Response criteria for lymphoma are described in Table 11.1 
Response Criteria for Multiple Myeloma  
Stringent Complete Response (sCR):  
 SCR requires, in addition to CR (defined below), all of the following  
 Normal free light chain  ration (FLC)  
 Absence of clonal cells in bone marrow by [CONTACT_207126] & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
66 
 Complete Response (CR) requires all of the following:  
 Absence of the original monoclonal paraprotein in serum and urine by [CONTACT_207127].  The presence of new monoclonal bands is 
consistent with oligoclonal immune reconstitution does not exclude CR:  
 Less than 5% plasma cells in a bone marrow aspi[INVESTIGATOR_207095], if 
biopsy is performed;  
 No increase in size  or number of lytic bone lesions on radiological investigations 
(development of a compression fracture dose not exclude CR)*; and,  
 Disappearance of soft tissue plasmacytomas.  
*If not clinically indicated, radiographs are not required to document CR.  
Patie nts in whom some, but not all, the criteria for CR are fulfilled are classified as partial 
responses (see below), providing the remaining criteria satisfy the requirements for partial 
response.  This includes patients in whom routine electrophoresis is neg ative but in whom 
immunofixation has not been performed.  
Near Complete Response  (nCR):  represents disease detected only by [CONTACT_207128]65,66  
 Presence of the original monoclonal paraprotein in serum and urine by [CONTACT_5294] 
 Less th an 5% plasma cells in a bone marrow aspi[INVESTIGATOR_207095], if 
biopsy is performed;  
 No increase in size or number of lytic bone lesions on radiological investigations 
(development of a compression fracture dose not exclude CR)  
 Very Good  Partial Response (VGPR) requires, in addition to PR (defined below), all of 
the following:Serum or urine paraprotein detectable by [CONTACT_207129],  
OR 
 Greater than or equal to 90% reduction in serum paraprotein plus urine parapro tein 
<100mg/24 hours  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
67 
 Partial Response (PR) requires one of the following:  
 Greater than or equal to 50% reduction in the level of the serum monoclonal paraprotein 
and/or reduction in 24 hour urinary monoclonal paraprotein either by [CONTACT_207130] 90% or to <200mg/24 hours in light chain deisease.  
 If the only measurable non -bone marrow parameter is FLC, greater than or equal to 50% 
reduction in the difference between involved and uninvolved FLC levels or a 50% 
decrease in level or involved FLC with 50% decrease in ratio.   
 If the bone marrow is the only measurable parameter, greater than or equal to 50% 
reduction in bone marrow plasma cells given that the baseline count was greater or equal 
to 30%.  
 Greater than or equal to 50% reduction in the size of  soft tissue plasmacytomas (by 
[CONTACT_207131]).  
 
Stable Disease (SD)  
 Patients who do not meet criteria for sCR, CR, VGPR, PR or progressive disease are 
considered to have stable disease (SD).  
 
Progression (PD)  from CR or sCR  requires o ne or more of the following:  
 A reappearance of serum monoclonal paraprotein, with a level of  at least 0.5 g/dL.  
 24-hour urine protein electrophoresis with at least 200 mg  paraprotein/24 hours.  
 Abnormal FLC levels of >10 mg/dl, only in patients without  meas urable paraprotein in 
the serum and urine.  
 At least 10% plasma cells in a bone marrow aspi[INVESTIGATOR_207096] . 
 Definite increase in the size of existing bone lesions or soft  tissue plasmacytomas.  
 Development of new bone lesions or soft tissue plasm acytomas.  
 Development of hypercalcemia (corrected serum Ca >11.5 mg/dL or  >2.8 mmol/L) not 
attributable to any other cause.  
 
Progressive Disease (PD)  for patients not in CR or sCR, progressive disease requires one or 
more of the following:  
 >25% increase i n the level of the serum monoclonal paraprotein, which must also be an 
absolute increase of at least 0.5 g/dL.  
 >25% increase in [ADDRESS_247026] 200 mg/24 hours.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
68 
  Absolute increase in  the difference between involved and uninvolved FLC levels 
(absolute increase must be >10 mg/dl), only in patients without measurable paraprotein in 
the serum and urine.  
 >25% increase in plasma cells in a bone marrow aspi[INVESTIGATOR_207097], which 
must also be an absolute increase of at least 10%.  
 Definite increase in the size of existing bone lesions or soft tissue plasmacytomas.  
 Development of new bone lesions or soft tissue plasmacytomas.  
 Development of a compression fracture does not exclude co ntinued response and may not 
indicate progression.  
 Development of hypercalcemia (corrected serum Ca >11.5 mg/dL or >2.8 mmol/L) not 
attributable to any other cause.  
 
Response Criteria for CML67 
Complete Hematologic response or remission (all must be presen t): 
 Platelet count <450,000/  uL 
 WBC count <10,000/UL  
 No immature neutrophils  
 <5% basophils  
 Spleen not palpable  
Cytogenetic Response  
 No response >95% Ph+ cells  
 Minor Response 36 -95% Ph+ cells  
 Major Response <35% Ph+ cells  
 
Molecular response/remission   
 
 Major response  >3 log reduction  
 
Complete response no BCR -ABL  transcript detectable  
 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
[ADDRESS_247027] three months from completion of therapy:  
• Absence of lymphadenopath y > 1.[ADDRESS_247028] scan;  
• No hepatomegaly or splenomegaly on physical exam (CT scan may be used to assess);  
• No clonal B -cells in the blood by [CONTACT_4133];  
• Normal CBC as exhibited by [CONTACT_164433] ≥ 1500/μL, platelets > 
100,000/μL, hemoglobin > 11.0 g/dL (untransfused); lymphocyte count < 5,000/μL;  
• Bone marrow aspi[INVESTIGATOR_164379] < 30% of nucleated cells 
being lymphocytes. Flow cytometry/immunohistochemistry should be performed on bone 
marrow. Lymphoid nodules may be present but must be T -cell in origin. If these are 
demonstrated to be clonal B -cells, patients should be considered a partial response. Addit ionally, 
if bone marrow is positive by [CONTACT_207132] a 
partial response. If the marrow is hypocellular a bone marrow should be performed in 2 -3 
months. If blood counts (polymo rphonuclear leukocytes < 1500/μL, platelets < 100,000/μL) fail 
to recover at the time of the response evaluation but there is otherwise no evidence of CLL 
otherwise, a repeat determination should be performed at the time of count recovery 
(polymorphonuclea r leukocytes ≥ 1500/μL, platelets > 100,000/μL) but no later than six months.  
• Patients who fulfill the criteria for CR after induction with the exception of a persistent 
cytopenia (CR with incomplete recovery, CRi) that is believed to be treatment relat ed will be 
considered a CRi. As stated above, patients falling into this category should ideally undergo a 
repeat bone marrow when counts recover fully. If the bone marrow at this time reveals no CLL, 
these patients will be considered to be in complete rem ission at that time. Additionally, patients 
who fulfill the criteria of CR with exception of having bone marrow lymphoid CLL nodules will 
be considered a CRi and assessed prospectively for the similarity to outcome with CR.  
Partial Response  
Requires a ≥ 50% decrease in peripheral lymphocyte count from pre -treatment value, ≥ 50% 
reduction in lymphadenopathy of as many as 6 measurable lymph nodes, and/or ≥ 50% reduction 
in splenomegaly/hepatomegaly for a period of at least two months. Patients may have bo ne 
marrow lymphoid nodules of B -cell origin. Additionally, these patients must have one of the 
following:  
• Polymorphonuclear leukocytes ≥ 1,500/μL or 50% improvement from pre -treatment value;  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
70 
 • Platelets > 100,000/μL or 50% improvement from pre -treatmen t value;  
• Hemoglobin > 11.0 g/dL (untransfused) or 50% improvement from pre -treatment value  
Progressive Disease  
Characterized by [CONTACT_207133]:  
• ≥ 50% increase in the products of at least two lymph nodes on two consecutive determina tions 
two weeks apart (at least one lymph node must be ≥ 2 cm); appearance of new palpable lymph 
nodes.  
• ≥ 50% increase in the size of the liver and/or spleen as determined by [CONTACT_207134]; appearance of palpable hepatom egaly or splenomegaly, which was not 
previously present.  
• ≥ 50% increase in the absolute number of circulating lymphocytes to at least 5,000/μL.CALGB 
100701/BMT CTN 0804 03/15/13 50   
• Transformation to a more aggressive histology (i.e., Richter’s syndr ome or prolymphocytic 
leukemia with ≥ 56% prolymphocytes).  
• Patients not fulfilling the above criteria for progressive disease but demonstrating a decrease in 
hemoglobin > 2 g/dL (or < 10 g/dL), decrease > 50% in platelet or granulocyte count will not be  
rated as progressive disease because these may occur as both a consequence of therapy and of 
underlying CLL. A bone marrow biopsy in such settings is strongly encouraged.  
Stable Disease  
Patients who do not fulfill the criteria for complete or partial re sponse as defined above but do 
not exhibit progressive disease will be considered as having stable disease.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
71 
 12.REFERENCES     
1. Malden M. Thomas' Hematopoeitic Cell Transplantation. 3rd ed ed. Blackwell 
Publishing; 2004.  
2. Szydlo R, Goldman JM, Klein JP et al. Results of allogeneic bone marrow transplants for 
leukemia using donors other than HLA -identical siblings. J Clin Oncol. 1997;15:1767 -
1777.  
3. Zuckerman T, Rowe JM. Alternative Donor transplantation in acute myeloid leukemia: 
which source and when? Curr.Opin .Hematol. 14, 152 -161. 2007.  
Ref Type: Generic  
4. Anasetti C, Amos D, Beatty PG et al. Effect of HLA compatibility on engraftment of 
bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med. 
1989;320:[ADDRESS_247029] 
disease, relapse, and survival after marrow transplantation for patients with leukemia or 
lymphoma. Hum Immunol. 1990;29:[ADDRESS_247030] decade (1991 -2000). 
Blood. 2003;102:1541 -1547.  
7. Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ. Graft rejection in recipi[INVESTIGATOR_22880] T -
cell-depleted HLA - nonidentical marrow transplants for leukemia. Identification of host -
derived antidonor allocytotoxic T lymphocytes. Transplantation. 1987;43:[ADDRESS_247031] disease. Blood. 
1986;68:770 -773. 
9. Aversa F, Tabilio A, Velardi A et al. Treatment of high -risk acute leukemia with T -cell-
depleted stem cells from related donors with one fully mismatched HLA haplotype [see 
comments]. N Engl J Med. 1998;339:1186 -1193.  
10. Aversa F, Terenzi A, Tabilio A et al. Full Haplotype -Mismatched Hematopoietic Stem -
Cell Transplantation: A Phase II Study in Patients With Acute Leukemia at High Risk of 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
72 
 Relapse. Journal of Clinical Oncology. 2005;23:3447 -3454.  
11. Mehta J,  Singhal S, Chiang KY, Godder K, Rhee FV, O'Neal W et al. Bone Marrow 
transplantation from partially HLA -mismatched family donors for acute leukemia: single -
center experience of [ADDRESS_247032]. 33, 389 -396. 2004.  
Ref Type: Generic  
12. Lang P, Greil J, Bader P et al. Long -term outcome after haploidentical stem cell 
transplantation in children. Blood Cells, Molecules, and Diseases. 2004;33:281 -287. 
13. Waller EK, Giver CR, Rosenthal H et al. Facilitating T -cell immune reconstitution after 
haploide ntical transplantation in adults. Blood Cells Mol Dis. 2004;33:233 -237. 
14. Guinan EC, Boussiotis VA, Neuberg D et al. Transplantation of anergic 
histoincompatible bone marrow allografts [see comments]. N Engl J Med. 
1999;340:1704 -1714.  
15. Rizzieri DA, Koh LP, Lo ng GD et al. Partially Matched, Nonmyeloablative Allogeneic 
Transplantation: Clinical Outcomes and Immune Reconstitution. Journal of Clinical 
Oncology. 2007;25:690 -697. 
16. Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections 
in recipi[INVESTIGATOR_207098]. Blood. 2003;102:827 -833. 
17. Dey BR, Spi[INVESTIGATOR_46030]. Current status of haploidentical stem cell transplantation. British 
Journal of Haematology. 2006;135:[ADDRESS_247033] reaction by 
[CONTACT_207135]: dependence on timing of drug administration. Bone Marrow 
Transplant. 1994;13:473 -477. 
19. Mayumi H, Umesue M, Nomoto K. Cyclophosphamide -induced immunological 
tolerance: a n overview. [Review] [74 refs]. Immunobiology. 1996;195:[ADDRESS_247034] disease. 
Transplantation. 1987;44: 286-290. 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
73 
 21. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major 
histocompatibility complex -incompatible cells after nonmyeloablative conditioning with 
fludarabine, low -dose total body irradiation, and posttransplantation cyclopho sphamide. 
Blood. 2001;98:[ADDRESS_247035]-transplantation cyclophosphamide 
facilitates engraftment of major histocompatibility complex -identical allogeneic marrow 
in mice conditioned with low -dose total body irrad iation. Biology of Blood and Marrow 
Transplantation. In press.  
23. O'Donnell PV, Luznik L, Jones RJ et al. Nonmyeloablative bone marrow transplantation 
from partially HLA -mismatched related donors using posttransplantation 
cyclophosphamide. Biol Blood Marrow T ransplant. 2002;8:377 -386. 
24. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell 
alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097 –2100.  
25. Pende D., Spaggiari G. M., Marcenaro S., et al. Analysis o f the receptor -ligand 
interactions in the natural killer -mediated lysis of freshly isolated myeloid or 
lymphoblastic leukemias: evidence for the involvement of the poliovirus receptor 
(CD155) and nectin -2 (CD112). Blood 2005; 105:2066 –2073.  
26. Pende D., Marce naro S., Falco M., et al. Anti-leukemia activity of alloreactive NK cells 
in KIR ligand -mismatched haploidentical HSCT for pediatric patients: evaluation of the 
functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 
2009; 1 13:3119 –3129.  
27. Moretta A., Locatelli F., Moretta L. Human NK cells: from HLA class I -specific killer 
Ig-like receptors to the therapy of acute leukemias. Immunol. Rev. 2008; 224:58 –69. 
28. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural  killer cell 
receptor genes leads to superior survival after unrelated transplantation for acute 
myelogenous leukemia. Blood. 2010;116(14):2411 -9. 
29. Symons HJ, Leffell MS, Rossiter ND, et al. Improved survival with inhibitory killer 
immunoglobulin receptor ( KIR) gene mismatches and KIR haplotype B donors after 
nonmyeloablative, HLA -haploidentical bone marrow transplantation. Biol Blood Marrow 
Transplant. 2010;16(4):533 -42. 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
74 
 30. Kröger N, Zabelina T, Berger J, et al.  Donor KIR haplotype B improves progression -free 
and overall survival after allogeneic hematopoietic stem cell transplantation for multiple 
myeloma.  Leukemia. 2011;25(10):1657 -61. 
31. Hallett WH, Ames E, Motarjemi M, et al.  Sensitization of tumor cells to NK cell -
mediated killing by [CONTACT_207136].   J Immunol. 2008 Jan 1;180(1):[ADDRESS_247036] A, Abrams SI, Schrump DS. et al. Bortezomib and depsipeptide sensitize 
tumors to tumor necrosis factor -related apoptosis -inducing ligand: a novel method to 
potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006;66:[ADDRESS_247037] and natural killer cell -mediated antitumor 
effects of low -dose bortezomib in hepatocellular carcinoma. Clin Cancer Res. 2008 Jun 
1;14(11):3520 -8. 
34. Shi J, Tricot GJ, Garg TK, et al. Bo rtezomib down -regulates the cell -surface expression 
of HLA class I and enhances natural killer cell -mediated lysis of myeloma.  Blood. 2008 
Feb 1;111(3):1309 -17. 
35. Wu X, Shao Y, Tao Y, et al. Proteasome inhibitor lactacystin augments natural killer cell 
cytotoxicity of myeloma via downregulation of HLA class I.  Biochem Biophys Res 
Commun. 2011 Nov 11;415(1):[ADDRESS_247038] cancer cells to natural 
killer cell -mediated cytotoxicity by [CONTACT_207136].   Clin Exp Immunol. 2009 
Mar;155(3):504 -13. 
37. Jardine L, Hambleton S, Bigley V, et al.  Sensitizing primary acute lymphoblastic 
leukemia to natural killer cell recognition by [CONTACT_207137]2D ligands.  Leuk 
Lymphoma. 2013 Jan;54(1):167 -73. 
38. Valés -Gómez M, C hisholm SE, Cassady -Cain RL, et al.  Selective induction of 
expression of a ligand for the NKG2D receptor by [CONTACT_207138].  Cancer Res. 
2008 Mar 1;68(5):[ADDRESS_247039] 
disease with retention of graft -versus -tumor effects by [CONTACT_207139]. Proc Natl Acad Sci U S A. 2004 May 25;101(21):8120 -5. 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
75 
 40. Blanco B, Pérez -Simón JA, Sánchez -Abarca LI, et al.  Bortezomib induces selective 
depletion of alloreacti ve T lymphocytes and decreases the production of Th1 cytokines.  
Blood. 2006 May 1;107(9):3575 -83. 
41. Blanco B, Pérez -Simón JA, Sánchez -Abarca LI, et al.  Treatment with bortezomib of 
human CD4+ T cells preserves natural regulatory T cells and allows the emer gence of a 
distinct suppressor T -cell population.  Haematologica. 2009 Jul;94(7):975 -83. 
42. Kim JS, Lee JI, Shin JY, et al.  Bortezomib can suppress activation of rapamycin -
resistant memory T cells without affecting regulatory T -cell viability in non -human 
primates.  Transplantation. 2009 Dec 27;88(12):[ADDRESS_247040];35(10):[ADDRESS_247041] disease 
prophylaxis in HLA -mismatched unrelated donor transplantation.  J Clin Oncol. 2012 
Sep 10;30(26):3202 -8. 
45. Kumar SK, Berdeja JG, Niesvizky R, et al.   A Phase 1/2 Study of Weekly MLN9708, an 
Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and 
Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM).  Blood 
(ASH Annual Meeting Abstracts) 2012 120: Abstract 33 2 
46. Ohata K, Espi[INVESTIGATOR_207099], Lu X, et al.  Mycophenolic acid inhibits natural killer cell 
proliferation and cytotoxic function: a possible disadvantage of including mycophenolate 
mofetil in the graft -versus -host disease prophylaxis regimen.  Biol Blood Marrow 
Transplant. 2011 Feb;17(2):205 -13. 
47. Gupta, N., et al., Clinical Pharmacokinetics of Intravenous and Oral MLN9708, An 
Investigational Proteasome Inhibitor: An Analysis of Data From Four Phase 1 
Monotherapy Studies.  Blood (ASH Annual Meeting Abstracts), 2010. 116(21): p. abstr 
1813.  
48. Gupta, N., M. Saleh, and K. Venkatakrishnan. Flat-Dosing Versus BSA -Based Dosing for 
MLN9708, An Investigational Proteasome Inhibitor: Population Pharmacokinetic (PK) 
Analysis of Pooled Data From [ADDRESS_247042] ASH Annual  Meeting and 
Exposition . 2011. San Diego, CA.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
76 
 49. Chow, L.Q., et al. MLN9708, an investigational proteasome inhibitor, in patients with 
solid tumors; Updated phase 1 results  in Head and Neck Symposium . 2012. Phoenix, AZ  
50. Assouline, S., et al. Once -weekly MLN970 8, an investigational proteasome inhibitor, in 
patients with relapsed/refractory lymphoma: results of a phase 1 dose -escalation study  in 
17th EHA Annual Congress . 2012. Amsterdam, the Netherlands.  
51. Lonial, S., et al. Phase I study of twice -weekly dosing of the investigational oral 
proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple 
myeloma (MM)  in ASCO  Annual Meetin g. 201 2. Chicago, Illinois.  
52. Kumar, S., et al. Oral weekly MLN9708, an investigational proteasome inhibitor, i n 
combination with lenalidomide and dexamethasone in patients (pts) with previously 
untreated multiple myeloma (MM): A phase I/II study  in ASCO  Annual Meetin g. 201 2. 
Chicago, Illinois.  
53. Merlini, G., et al. MLN9708, a Novel, Investigational Oral Proteasome I nhibitor, in 
Patients with Relapsed or Refractory Light -Chain Amyloidosis (AL): Results of a Phase 1 
Study  in 54th ASH Annual Meeting and Exposition . 2012. Atlanta, Georgia.  
54. Kumar, S. et al. A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral 
Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients 
with Previously Untreated Multiple Myeloma (MM)  in 54th ASH Annual Meeting and 
Exposition . 2012. Atlanta, Georgia.  
55. Richardson, P.G., et al. MLN9708, an investigational proteas ome inhibitor, in 
combination with lenalidomide and dexamethasone in previously untreated multiple 
myeloma patients (pts):  
Evaluation of weekly and twice -weekly dosing  in 17th EHA Annual Congress . 2012. 
Amsterdam, the Netherlands.  
56. San Miguel, J., et al. Oral MLN9708, an an investigational proteasome inhibitor, in 
combination with melphalan and prednisone in patients with previously untreated 
multiple myeloma: a phase 1 study  in 17th EHA Annual Congress . 2012. Amsterdam, the 
Netherlands.  
57. Kumar S., et al. Weekly Dosing of the Investigational Oral Proteasome Inhibitor 
MLN9708 in Patients with Relapsed and/or Refractory Multiple Myeloma: Results From 
a Phase [ADDRESS_247043] ASH Annual Meeting and Exposition.  2011. San 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
77 
 Diego, CA  
58. Kumar S., et al. Weekly dosing of the investigational oral proteasome inhibitor MLN9708 
in patients (pts) with relapsed/refractory multiple myeloma (MM): A phase I study in 
ASCO Annual Meeting . 2012. Chicago, Illinois.  
59. Sanchorawala V. , et al.  Poster Presentation: Phase 1 st udy of MLN9708, a novel, 
investigational oral proteasome inhibitor, in patients with relapsed or refractory light -
chain amyloidosis . XIII International Symposium on Amyloidosis, Groningen, The 
Netherlands 2012.  
60. Common Terminology Criteria for Adverse Event s (CTCAE) . 2010.  
61. Luznik L, O'Donnell PV, Symons HJ, et al.  HLA -haploidentical bone marrow 
transplantation for hematologic malignancies using nonmyeloablative conditioning and 
high-dose, posttransplantation cyclophosphamide.  Biol Blood Marrow Transplant. 2008 
Jun;14(6):641 -50. 
62. Disease evaluation criteria for leukemia and lymphoma taken from BMT CTN 1101 
Multi -Center, Phase III, Randomized Trial of Reduced Intensity Conditioning (RIC) and 
Transplantation of Double Unrelated Umbilical Cord Blood versus HLA -Haploidentical 
Related Donor Bone Marrow for Patients with Hematologic Malignancies  
63. Disease evaluation criteria for multiple myeloma taken from BMT CTN [ADDRESS_247044] on the outcome of multiple myeloma patients. British Journal of 
Haematology. 2000; 109(2):438 -46. 
65. Richardson PG, Barlogie B, Berensoin J, Singhai S, Jagannath S, Irwin D, et al.  A Phase 
2 Study of Boretzomib in Relapsed, Refractory Myeloma.  N Engl J Med. 
2003:348(26):2609 -17. 
66. Cheson, B.D. et al.  Revised response criteria for malignant lymphoma.  J Clin Oncol  
5:579 -586, 2007.  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
78 
 67. Response criteria for CML taken from CIBMTR 2011 Tandem Meeting presentation  
68. Response criteria for CLL taken from CIB MTR 100701 Phase II Study of Reduced -
Intensity Allogeneic Stem Cell Transplant For High -Risk Chronic Lymphocytic 
Leukemia (CLL)  
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
79 
 13. APPENDICES  
13.1   Appendix 1: Karnofsky Performance Status Scale  
Index  Specific Criteria  General  
100 Normal, no complaints, no evi dence of disease.  
 Able to carry on normal activity; no 
special care needed.  
[ADDRESS_247045] needs.  
50 Requires considerable assista nce from others 
and frequent medical care  
40 Disabled, requires special care and assistance.  Unable to care for self, requires 
institutional or hospi[INVESTIGATOR_180855], disease may be rapi[INVESTIGATOR_180856].  
 30 Severely disabled, hospi[INVESTIGATOR_207100], but 
death not imminent.  
20 Very sick, hospi[INVESTIGATOR_20545], active 
supportive treatment necessary.  
10 Moribund  
0 Dead  
 
Blood & Marrow Transplant Program  at Clinical Study Protocol X16035  
Northside Hospi[INVESTIGATOR_307]     
80 
  
 
13.2   Appendix 2: Group B KIR Haplotype Determination  
Group A and B KIR haplotypes have distinctive centromeric (Cen) and telomeric (Tel) gene -
content motifs. With the goal of developi[INVESTIGATOR_007] a donor selection strategy to improve transplant 
outcome, Cooley et al., compared the contribution of these motifs to the clinical benefit 
conferred by B haplotype donors28.  Compared to A haplotype motifs, centromeric and telomeric 
B motifs both contributed to relapse protection and improved survival, but Cen -B homozygosity 
had the strongest independent effect.  
 
A donor KIR B -content group calculator  is available through the Immuno Polym orphism 
Database (IPD) project, established by [CONTACT_207140]; and can be 
accessed through the following website: http://www.ebi.ac.uk/ipd/kir/donor_b_content.html . 
   
 
 
 
13.3    Sample SAE Form  
(A sample Serious Adverse Event Form is attached. ) 
 
13.4  Millennium Pregnancy Reporting Form  
(A sample Pregnancy Form  is attached)   